Cancer Incidence and Mortality in New Jersey 1999 - 2003

Prepared by:
Stasia S. Burger, MS, CTR
Xiaoling Niu, MS
Lisa M. Roche, MPH, PhD
Susan Van Loon, RN, CTR
Betsy A. Kohler, MPH, CTR

Cancer Epidemiology Services
Center for Cancer Initiatives
New Jersey Department of Health and Senior Services

Eddy A. Bresnitz, MD, MS
Deputy Commissioner/State Epidemiologist
New Jersey Department of Health and Senior Services

Fred M. Jacobs, MD, JD
Commissioner
New Jersey Department of Health and Senior Services

Richard J. Codey
Acting Governor

Cancer Epidemiology Services
New Jersey Department of Health and Senior Services
PO Box 369
Trenton, NJ 08625-0369
(609) 588-3500
http://nj.gov/health/ces/index.shtml

December 2005

ACKNOWLEDGMENTS

The following staff of the New Jersey State Cancer Registry and the Cancer Surveillance Program of the Cancer Epidemiology Services were involved in the collection, quality assurance and preparation of the data on incident cases of cancer in New Jersey:

Pamela Agovino, MPH
Anne Marie Anepete, CTR
Pamela Beasley
Tara Blando
Donna Brown, CTR
Emiliano Cornago
Kathleen Diszler, RN, CTR
Thomas English, CTR
Lorraine Fernbach, CTR
Ruthann Filipowicz
Raj Gona, MPH, MA
Maria Halama, MD, CTR
Essam Hanani, MD
Marilyn Hansen, CTR
Kevin Henry, PhD
Joan Hess, RN, CTR
Margaret Hodnicki, RN, CTR
Yvette Humphries
Nicole Jackson
Linda Johnson, CTR
Anna Jones
Catherine Karnicky, CTR
Harrine Katz, CTR
Thuy Lam, MPH
Henry Lewis, MPH
Helen Martin, CTR
Ilsia Martin, MS
Kevin Masterson, CTR
Carl C. Monetti
John Murphy, CTR
Lisa Paddock, MPH
Maithili Patnaik, CTR
Theresa Pavlovcak, CTR
Karen Pawlish, MPH, ScD
Barbara Pingitor
Gladys Pyatt-Dickson, CTR
Karen Robinson-Frasier, CTR
Antonio Savillo, MD, CTR
Suzanne Schwartz, MS, CTR
Rekha Tharwani, MD, CTR
Celia Troisi, CTR
Helen Weiss, RN, CTR
Michael Wellins
Homer Wilcox III

We also acknowledge New Jersey hospitals, laboratories, physicians, dentists, and the states of Delaware, Florida, Maryland, New York, North Carolina, and Pennsylvania who reported cancer cases to the New Jersey State Cancer Registry.

Cancer Epidemiology Services, including the New Jersey State Cancer Registry, receives support from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute under contract N01-PC-45025-40, the National Program of Cancer Registries, Centers for Disease Control and Prevention under cooperative agreement U55/CCU221914-03, and the State of New Jersey.

TABLE OF CONTENTS

TABLES

INTRODUCTION

The following tables present statewide, age-adjusted incidence rates and counts for all cancers diagnosed among New Jersey residents during the period 1999-2003, age-adjusted mortality rates and counts for the period 1999-2002 and comparisons of state and national rates for 1998-2002. The New Jersey cancer incidence data for 2003 are considered preliminary. U.S. cancer incidence data and cancer mortality data for 2003 are not yet available.

The primary goal of this report is to provide 1999-2003 cancer data to health planners, researchers and the public. Data are provided statewide for six population subgroups: white men, white women, black men, black women, Hispanic men and Hispanic women. Data are also provided by gender for all races combined.

For each year, the age-adjusted incidence and mortality rates per 100,000 population are shown for 67 categories of cancer and for all sites combined. For the incidence counts and rates, *in situ* cancers are not included except for bladder cancer *in situ* cases, which are included with invasive urinary bladder, urinary system and all sites. Breast cancer *in situ* cases for women are shown but not included in the totals for all sites combined. Basal and squamous cell skin cancers are not collected and therefore not included in the data tables. These conventions are standard practice for publication of cancer rates in the United States.

Additional New Jersey cancer incidence, mortality, and survival data are available, or will be soon, from the Cancer Epidemiology Services office or on our website, http://nj.gov/health/ces/index.shtml, including:

- *Trends in Cancer Incidence and Mortality in New Jersey 1979-2002;*
- *Cancer Incidence Rates in New Jersey's Ten Most Populated Municipalities 1998-2002*;
- *Childhood Cancer in New Jersey 1979-2002*; and
- *Cancer Survival in New Jersey 1979-1997*.

Our new interactive cancer data mapping application provides incidence and mortality counts and rates statewide and at the county level by year, age, sex, race, and ethnicity for the years 1998-2002 at http://www.cancer-rates.info/nj/. This application will be updated with the 1999-2003 data shortly. Other New Jersey and U.S. cancer data can be found on the following websites:

- Cancer Control Planet http://cancercontrolplanet.cancer.gov/
- North American Association of Central Cancer Registries' *Cancer in North America 1998-2002* http://www.naaccr.org/index.asp?Col_SectionKey=11&Col_ContentID=49
- Surveillance, Epidemiology and End Results Program (SEER) Cancer Statistics http://surveillance.cancer.gov/statistics/

SUMMARY

NEW JERSEY CANCER INCIDENCE AND MORTALITY DATA, 1999-2003

A total of 45,248 cases of invasive cancer diagnosed in 2003 among New Jersey residents were reported to the New Jersey State Cancer Registry (NJSCR), compared to 46,708 reported cases diagnosed in 2002. During the period 1999-2003, a total of 231,361 cases of invasive cancer were diagnosed among New Jersey residents, 51 percent among men and 49 percent among women.

In New Jersey, between 1999 and 2003, overall age-adjusted total cancer incidence rates increased for men and women through 2001 and then declined, while national cancer incidence rates for both men and women remained stable through 2002. New Jersey black men continued to have the highest cancer incidence rates, and black women continued to have the lowest cancer incidence rates for all sites combined. The lower New Jersey incidence rates for prostate cancer in 2003, compared to earlier years, may be due to reduced screening, delays in reporting or for other reasons currently unknown. Incidence rates for thyroid cancer continued to increase statewide between 1999 and 2003, especially among white and black women. New Jersey Hispanics continued to have lower incidence rates for all cancers combined and for many of the most common types of cancer in the general population including lung, colorectal, breast, bladder, and melanoma of the skin. Hispanics also continued to have higher incidence rates for cervical, stomach and liver cancers compared with the general population.

Comparing New Jersey and U.S. age-adjusted incidence rates using data published in *Cancer in North America* by the North American Association of Central Cancer Registries (NAACCR) for 1998-2002, New Jersey incidence rates for all cancers combined continued to be higher than the U.S. rates. New Jersey had higher incidence rates compared to the U.S. for the most common cancers with some exceptions. New Jersey incidence rates were lower than U.S. rates for male lung cancer among whites, blacks and all races combined, melanoma among black men and women and breast cancer among black women.

Among New Jersey residents, a total of 17,827 deaths occurred in 2002 for which cancer was designated on the death certificate as the underlying cause, compared to 18,164 reported cancer deaths in 2001. During the period 1999-2002, a total of 72,240 cancer deaths occurred among New Jersey residents, 49 percent among men and 51 percent among women. In New Jersey, between 1999 and 2002, overall age-adjusted cancer mortality rates continued to slowly decline, similar to the trend observed throughout the nation.

New Jersey cancer mortality rates for men continued to be higher than for women. Cancer mortality rates for black men continued to be higher than for white men. Among black women, cancer mortality rates continued to be slightly higher compared to white women. Overall cancer mortality rates for New Jersey Hispanic men and women were much lower than for all men and women in New Jersey except for liver cancer, for which the rate was slightly higher. Mortality rates were generally higher for Hispanic men compared with Hispanic women, which is consistent with the pattern seen among all races/ethnicities combined.

For the period 1998-2002, the New Jersey cancer mortality rate for all cancer sites combined was higher than the corresponding rate for the U.S. for both men and women. However, lung and colorectal cancer mortality rates among men for all races combined, whites, and blacks, were lower for New Jersey than the U.S. New Jersey black men continued to have lower mortality rates for the most common cancers compared to U.S. black men. Among women, the cancer mortality rates for all sites combined, breast and colorectal cancers were higher for New Jersey than the U.S. during this period. Lung cancer mortality rates for New Jersey women were similar to the corresponding rates for the U.S., while breast and colorectal cancer mortality rates among black women were lower than among U.S. black women.

TECHNICAL NOTES

New Jersey State Cancer Registry (NJSCR)

NJSCR Overview

The objectives of the New Jersey State Cancer Registry (NJSCR) are to:

* monitor cancer trends in New Jersey;
* promote scientific research;
* respond to New Jersey residents about cancer concerns;
* educate the public;
* provide information for planning and evaluating cancer prevention and control activities; and
* share and compare cancer data with other states and the nation.

The New Jersey State Cancer Registry is a population-based cancer incidence registry that serves the entire state of New Jersey, which has a current estimated population of over 8.6 million people. The NJSCR was established by legislation (NJSA 26:2-104 et. seq.) and includes all cases of cancer diagnosed in New Jersey residents since October 1, 1978. New Jersey regulations (NJAC 8:57A) require the reporting of all newly diagnosed cancer cases to the NJSCR within three months of hospital discharge or six months of diagnosis, whichever is sooner. Reports are filed by hospitals, diagnosing physicians, dentists, and independent clinical laboratories. Every hospital in New Jersey reports cancer cases electronically. In addition, reporting agreements are maintained with New York, Pennsylvania, Delaware, Florida, Maryland, and North Carolina so that New Jersey residents diagnosed with cancer outside the state can be identified. Legislation passed in 1996 strengthened the Registry by: requiring electronic reporting; requiring abstracting by certified tumor registrars; and establishing penalties for late or incomplete reporting.

All primary invasive and *in situ* neoplasms are reportable to the NJSCR, except cervical cancer *in situ* diagnosed after 1994 and certain carcinomas of the skin. The information collected by the NJSCR includes basic patient identifiers, demographic characteristics of the patient, medical information on each cancer diagnosis (such as the anatomic site, histologic type and stage of disease), first course of treatment and vital status (alive or deceased) determined annually. For deceased cases, the underlying cause of death is also included. The primary site, behavior, grade, and histology of each cancer are coded according to the *International Classification of Diseases for Oncology (ICD-O), 2nd edition* for cancers diagnosed through 2000 and the *3rd edition* for cancers diagnosed after 2000. The NJSCR follows the data standards promulgated by the North American Association of Central Cancer Registries (NAACCR), including the use of the Surveillance, Epidemiology, and End Results (SEER) multiple primary rules. An individual may develop more than one cancer. Following the SEER multiple primary rules, patients could therefore be counted more than once if they were diagnosed with two or more primary cancers.

The NJSCR is a member of the North American Association of Central Cancer Registries (NAACCR), an organization that sets standards for cancer registries, facilitates data exchange, and publishes cancer data. The NJSCR has been a participant of the National Program of Cancer Registries (NPCR) sponsored by the Centers for Disease Control and Prevention (CDC) since it began in 1994 and is a National Cancer Institute (NCI) SEER Registry.

NJSCR Data Quality

NAACCR has awarded the Gold Standard, the highest standard possible, to the NJSCR for the quality of the data for each year 1995 through 2002. The NJSCR has consistently achieved the highest level of certification for its data since the inception of this award. The criteria used to judge the quality of the data are completeness of cancer case ascertainment, completeness of certain information on the cancer cases, percent of death certificate only cases, percent of duplicate cases, passing an editing program, and timeliness.

Completeness of reporting to the NJSCR was estimated by comparing New Jersey and U.S. incidence to mortality ratios for whites and blacks, standardized for age, gender, and cancer site. The data used to generate these ratios were the cancer incidence rates for all SEER registries combined. Using these standard formulae, it is possible for the estimation of completeness to be greater than 100 percent. For 2003 data, the completeness of case reporting was estimated as 100.8 percent at the time this report was prepared.

While our estimates of completeness are very high, some cases of cancer among New Jersey residents who were diagnosed and/or treated in out-of-state facilities may not yet have been reported to the NJSCR by other state registries. This should be considered in interpreting the data for the more recent years. However, these relatively few cases will not significantly affect the cancer rates, or alter the overall trends presented in this report.

Other 2003 cancer incidence data quality indicators measured were as follows:

percent death-certificate-only cases - 1.4 percent;
percent of unresolved duplicates - < 0.1 percent;
percent of cases with unknown race - 1.5 percent;
percent of cases with unknown county - 0.13 percent;
number of cases with unknown age - 6; and
number of cases with unknown gender - 3.

It should also be noted that there may be minor differences in the New Jersey incidence and mortality rates in this report compared to previous reports, due to ongoing editing and review of the data. Compared to preliminary data for 2002 published in our last report, 2002 incidence rates for total cancer in this report increased by 0.3 percent for men and 0.8 percent for women. Similarly, the 2003 incidence rates presented here are expected to increase by the time all data are complete, and therefore are considered preliminary.

The NJSCR continues to work toward improving the quality and number of its reporting sources. Over the past few years, significant improvements have been realized in this regard. For example

some of these improvements have resulted in better reporting of skin cancers such as melanoma. One of the most significant improvements has been the implementation of electronic pathology laboratory reporting (E-path) from a national pathology laboratory and several hospital-based laboratories. The ultimate goal is to enable E-path laboratory reporting from every laboratory that serves New Jersey. E-path reporting is expected to improve the timeliness and completeness of cancer reporting, especially for non-hospitalized cases.

Data Sources

Incidence and Mortality Data

New Jersey cancer incidence data were taken from the November 2005 analytic file of the New Jersey State Cancer Registry. All the counts and rates were tabulated using SEER*Stat Version 6.1 (http://www.seer.cancer.gov/seerstat/), a statistical software package distributed by the National Cancer Institute. New Jersey cancer mortality data were obtained through the NCI 's Surveillance, Epidemiology, and End Results (SEER) Program from the National Center for Health Statistics (NCHS) and also tabulated using SEER*Stat. At the time of this report, year 2003 mortality data were not yet available. U.S. cancer incidence and mortality data were obtained from NAACCR's publication, *Cancer in North America 1998-2002* (http://www.naaccr.org/index.asp?Col_SectionKey=11&Col_ContentID=50).

Population Estimations

The 1999-2003 population estimates for this report were provided by the National Cancer Institute's SEER Program and downloaded from the SEER's website http://seer.cancer.gov/popdata/. Since the 2003 population data were not available at the time the 2003 incidence rates were calculated, 2002 population data were used for 2003.

Population Denominators for 2000

With the inclusion of the year 2000 population data, we must take into account the new way in which the U.S. Bureau of the Census collected population data. With the 2000 Census, individuals were given the opportunity to categorize themselves as more than one race. For the first time, individuals could "mark [X] one or more races to indicate what this person considers himself/herself to be." Because of this change, 2000 population estimates for "White only" and "Black only" in earlier cancer incidence and mortality reports, are 4-6 percent lower than the 1999 populations for "White only" and "Black only" in New Jersey. Therefore, the NJSCR cautions the reader that when comparing the age-adjusted incidence rates for 2000, 2001 and 2002 by race to earlier years, it is not clear if an apparent rate change is actual or an artifact of the new way in which the U.S. Bureau of the Census collected race data for 2000.

The population estimates now incorporate bridged single-race estimates for July 1, 2000, 2001 and 2002, which are derived from the original multiple race categories in the 2000 Census (as specified in the *1997 Office of Management and Budget Standards* for the collection of data on race and ethnicity). For agencies such as NCI and NCHS to continue reporting long-term trends in disease rates for single-race groups, a method is needed to "bridge" these multi-race

classifications into a single-race category. Such a method was developed by NCHS using information collected as part of their National Health Interview Surveys. In collaboration with NCHS, the Census Bureau produced a set of year 2000 population estimates that assigned everyone to one race group only. The resulting 2000 estimates were then used to produce an improved set of 1991-2002 population estimates.

The bridged single-race estimates and a more in-depth description of the methodology used to develop them appear on the National Center for Health Statistics (NCHS) web site located at the following link:

http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm

In addition, 2000 population estimates used to calculate rates for the years 1991 through 1999 for previous reports have been found to differ from the actual 2000 census counts, especially the specific race and ethnicity estimates. Therefore, the 1991-1999 intercensal population estimates were revised by the Census Bureau by distributing the difference between the original post-1990 census estimates of the 2000 population and the actual April 1, 2000 census. The new population estimates affected primarily smaller populations such as race or Hispanic ethnicity subgroups.

Data Specifications

Exclusions

For this report, cases where the county of residence is unknown were excluded from the New Jersey rates and counts, in accordance with the standard procedures used by SEER, and has been determined to have little effect on the incidence rates. For example, the total number of cases with unknown county for 1999-2003 is 197, representing 0.08% of the total case population. The small numbers of cases with unknown age, gender or race were also excluded from the analyses. Since the number of records so affected was very small, the rates were virtually unaffected by the non-inclusion of these records. Race-specific information is not shown separately for persons who are races other than white or black (including unknown race), but these persons are included in the "all races" data. Only invasive cancers were included in the incidence data, except *in situ* bladder cancers were included.

Incidence and Mortality Coding

Beginning with the year 2001, the coding scheme for incident cancer cases changed from the *International Classification of Diseases for Oncology, 2nd edition (ICD-0-2)* to the *3rd edition* (*ICD-0-3*). The primary effect of the coding change is that borderline ovarian cancer cases were not included in the data from 2001 on, but were included for the previous years, 1979-2000 for both New Jersey and the U.S. This resulted in about 100 fewer cases per year included for years 2001-2003 in New Jersey. Several newly reportable cancers were added to the *ICD-0-3* manual and are presently being grouped under "Ill-Defined and Unspecified" sites. The addition of chronic myeloproliterative disorders and myelodysplastic syndromes are responsible for a marked increase in the "Ill-Defined and Unspecified" sites in 2001-2003 from previous years.

The following SEER web link contains additional information on the transition from *ICD-0-2* to *ICD-0-3*:

http://training.seer.cancer.gov/module_icdo3/downloadables/ICDO3%20abstract%20n%20article%20NEW%20PDF.pdf

Beginning with the year 1999, coding and classification for cause of death is in accordance with the *10th edition* of the World Health Organization's *International Classification of Diseases (ICD-10)*. From 1979-1998, cause of death coding is based on the 9th *edition (ICD-9)*. Changes in classification detail, coding rules, and classification code numbers with this new version have caused some discontinuities in trends for cancer deaths. Although these discontinuities vary, research has found that using ICD-10 assigns approximately 0.7 percent more deaths to the category of cancer, which may slightly increase some site-specific mortality rates for 1999 and later.

Description of Algorithm for Designating Hispanic Ethnicity

In 2003, the NJSCR adopted the NAACCR Hispanic Identification Algorithm (NHIA) to assign Hispanic ethnicity to cases. This method uses data on birthplace, marital status, gender, race and surname match to the 1990 Hispanic surname list to augment the number of cases and decedents reported as Hispanic in the registry during the years 1994-2003.

In 2005, NAACCR made several revisions to NHIA, now NHIA version 2. The most significant change in NHIA version 2 was the addition of an option for registries to not apply the algorithm to counties in which the Hispanic population is less than five percent. The New Jersey State Cancer Registry determined that this option did not enhance the accuracy of the NHIA and therefore opted not to apply this option. Thus, using NHIA version 2 will not affect the New Jersey cancer rates among Hispanics.

Prior to the development of the NHIA, the NJSCR used a method to assign Hispanic ethnicity to cases that was adapted from algorithms developed by the Illinois State Cancer Registry (ISCR) and by the NJSCR. NHIA is closely related to these former algorithms, so there is high agreement between the cases previously determined to be Hispanic and those currently determined to be Hispanic.

As a result of using the NHIA, the NJSCR was able to increase the number of Hispanic cases by 23 percent for this time period, thereby correcting an under-identification of Hispanics. For a more complete description of the NHIA version 2 and a copy of the NHIA SAS program visit the following link at the NAACCR website:

http://www.naaccr.org/index.asp?Col_SectionKey=7&Col_ContentID=312#Hispanic

Caution should be used when comparing rates among Hispanics with the rates in the different race groups (e.g. black, white) because ethnicity and race are not mutually exclusive. In New Jersey, the majority (89 percent) of Hispanics identify themselves as white. The Hispanics who identify themselves as white are included in the white race category as well as the all races category.

Caution should also be used when comparing Hispanic mortality data to Hispanic incidence data in this report. Hispanic mortality data for this report were obtained from NCI's SEER Program and did not have the NHIA algorithm applied to them. In our detailed report, *Cancer Among Hispanics in New Jersey, 1990-1996*, our previous Hispanic algorithm was applied to mortality data from the New Jersey Center for Health Statistics, resulting in an increased mortality rate of 13 percent for men and 23 percent for women.

Data Presentation

Suppression of Rates and Counts Under Five

It should also be noted that the annual rates for relatively uncommon cancers tend to fluctuate substantially from year to year because of small numbers of cases, particularly in minority populations. Rates generated from small numbers should be interpreted with caution. For this report, rates were suppressed where counts were less than 5 as a way to ensure a greater level of statistical reliability and patient confidentiality.

Calculation of Rates

Age-adjusted Rates and the Year 2000 Standard

The U.S. Department of Health and Human Services requires that health data be age-adjusted using the U.S. Year 2000 population as a standard, beginning with the 1999 reporting year. Age-adjustment to the year 2000 population as the standard has been used in our last three annual reports. Prior to the release of 1999 data, various federal and state agencies calculated disease rates using different U.S. population standards, including the 1940 and 1970 standard populations. Our report *Cancer Incidence and Mortality in New Jersey, 1995-1999*, issued in September 2001, used the former 1970 population standard for all five years and also illustrated the effect on 1999 incidence rates of changing the population standard from 1970 to 2000.

Calculations using the 2000 standard population do not indicate a change in cancer incidence or occurrence—only a different representation of the rates of reported cancer. Using the 2000 population as the standard produces standardized cancer rates that appear to be about 20 percent higher than previously reported.

In this report, the 2000 U.S. Std. Population (19 age groups-Census P25-1130) was used for age-adjustment instead of the 2000 U.S. Std. Million (19 age groups). This has been standard practice for all NCI SEER reports with incidence or mortality data for 2002 or later. This new population standard was created for use with single year of age population data. Differences in the age-adjusted rates using the 2000 Std. Million and the new 2000 U.S. Std. Population are minimal. For further details, see SEER's website located at the following link http://seer.cancer.gov/stdpopulations/single_age.html.

Rate Calculation Formulas

A cancer incidence rate is defined as the number of new cases of cancer detected during a specified time period in a specified population. Cancer rates are most commonly expressed as cases per 100,000 population. Cancer occurs at different rates in different age groups, and population subgroups defined by gender and race have different age distributions. Therefore, before a valid comparison can be made between rates, it is necessary to standardize the rates to the age distribution of a standard population.

The first step in the age-standardization procedure is to determine the age-specific rates. For each age group for a given time interval (within each race-gender group, for the entire state), the following formula is applied:

$$r_a = \frac{n_a}{t \; x \; P_a}$$

where

- r_a = the age-specific rate for age group a,
- n_a = the number of events (cancer diagnoses) in the age group during the time interval,
- t = the length of the time interval (in years), and
- P_a = average size of the population in the age group during the time interval (mid-year population or average of mid-year population sizes).

In order to determine the age-adjusted rate, a weighted average of the age-specific rates is calculated, using the age distribution of the standard population to derive the age-specific weighting factors (Rothman, 1986). This is the technique of direct standardization, which uses the following formula:

$$R = \frac{\sum_{a=1}^{n} r_a \; x \; Std.P_a}{\sum_{a=1}^{n} Std.P_a}$$

where

- R = the age-adjusted rate,
- r_a = the age-specific rate for age group a, and
- $Std.P_a$ = the size of the standard population in each age group a.

While age standardization facilitates the comparison of rates among different populations, there can be important age-specific differences in disease occurrence, which are not apparent in comparisons of the age-adjusted rates (Breslow and Day, 1987).

Analogous definitions and calculations apply for cancer mortality rates.

References

Breslow NE and Day NE. *Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies***.** New York: Oxford University Press.1987.

Chiang CL. "Standard error of the age-adjusted death rate". In Vital Statistics Special Reports, Volume 47, Number 9**.** USDHEW, PHS, Washington, D.C. U.S. Government Printing Office, 1961.

Edwards BK, Brown ML, Wingo PA et al. Annual report to the Nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005; 97:1407-27.

Ellison JH, Wu XC, Howe HL et al (eds). Cancer in North America, 1998-2002 Volumes 1-4. North American Association of Central Cancer Registries, April 2005. [URL. http://www.naaccr.org/index.asp?Col_SectionKey=11&Col_ContentID=50, accessed October 26, 2005]

Fritz A., Percy C. Implementing ICD-O-3: Impact of the New Edition. SEER Program, National Cancer Institute. [URL. http://training.seer.cancer.gov/module_icdo3/downloadables/ICDO3%20abstract%20n%20article%20NEW%20PDF.pdf , accessed October 26, 2005]

Ingram DD, Parker JD, Schenker N et al. United States Census 2000 population with bridged race categories. National Center for Health Statistics. Vital Health Stat 2(135). 2003. [URL. http://www.cdc.gov/nchs/data/series/sr_02/sr02_135.pdf, accessed October 26, 2005]

Martin, RM. "Age standardization of death rates in New Jersey: Implications of a change in the standard population". Topics in Health Statistics. Center for Health Statistics. 2000;01-02.

National Center for Health Statistics. U.S. census population with bridged race categories, September 2004. [URL. http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm, accessed October 26, 2005]

North American Association of Central Cancer Registries. Registry Operation Guidelines-Hispanic Identification. Springfield, Illinois: U.S. [URL. http://www.naaccr.org/index.asp?Col_SectionKey=7&Col_ContentID=312, accessed October 26, 2005]

Rothman K. *Modern Epidemiology*. U.S. Little, Brown, and Company. 1986.

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). Population estimates used in NCI's SEER*Stat software, January, 2004. [URL http://seer.cancer.gov/popdata/methods.html, accessed October 26, 2005]

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Public-Use With State, Total U.S. (1969-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005. Underlying mortality data provided by NCHS (www.cdc.gov/nchs). [URL. http://seer.cancer.gov/mortality/, accessed October 26, 2005]

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Populations - Total U.S. (1969-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005. [URL. http://seer.cancer.gov/popdata/, accessed October 26, 2005]

Surveillance Research Program, National Cancer Institute Seer*Stat software Version 6.1. [URL. http://seer.cancer.gov/seerstat/, accessed October 26, 2005]

The United States Census Bureau. "Major differences in subject-matter content between 1990 and 2000 Census questionnaires-race", October 2003. [URL. http://www.census.gov/population/www/cen2000/90vs00.html, accessed October 26, 2005]

Weinstein R, Lee YS and Klotz J. *Cancer Among Hispanics in New Jersey 1990-1996.* New Jersey Department of Health and Senior Services, June 2000. [URL. http://www.state.nj.us/health/cancer/hispanic/, accessed October 26, 2005]

Table 1. Age-adjusted Incidence Rates, Males All Races Combined

Cancer Site	Total Cases	Rates 1999	2000	2001	2002	2003 Prelim.
All Sites	118,981	624.3	626.8	654.8	644.2	596.5
Oral Cavity and Pharynx	2,900	14.5	15.4	14.7	14.7	14.2
Lip	125	0.6	0.7	0.8	0.9	0.4
Tongue	845	3.9	4.1	4.4	4.2	4.4
Salivary Gland	308	1.4	1.8	1.8	1.6	1.6
Floor of Mouth	196	1.2	0.8	1.0	1.0	0.8
Gum and Other Mouth	370	1.8	2.0	1.8	1.9	2.0
Nasopharynx	193	1.1	1.1	0.8	0.9	1.0
Tonsil	393	1.6	2.1	1.8	1.9	2.1
Oropharynx	114	0.6	0.9	0.3	0.7	0.4
Hypopharynx	271	1.5	1.6	1.6	1.1	1.2
Digestive System	23,353	131.3	126.5	127.3	123.4	119.8
Esophagus	1,632	8.7	8.9	8.6	8.0	8.6
Stomach	2,529	15.2	12.5	13.9	14.0	12.7
Small Intestine	436	2.3	2.2	2.3	2.3	2.2
Colon and Rectum	13,557	78.7	75.9	73.4	71.6	67.8
Colon excluding Rectum	9,393	55.6	52.8	51.4	49.9	47.4
Rectum and Rectosigmoid Junction	4,164	23.0	23.1	22.0	21.7	20.4
Anus, Anal Canal and Anorectum	207	1.2	0.7	1.0	1.3	1.2
Liver and Intrahepatic Bile Duct	1,692	7.2	8.9	9.8	8.8	9.4
Liver	1,542	6.3	7.9	8.9	8.2	8.7
Intrahepatic Bile Duct	150	0.9	1.0	0.9	0.6	0.7
Gallbladder	190	0.8	1.0	1.1	0.9	1.4
Pancreas	2,542	14.1	13.6	14.3	13.3	13.4
Respiratory System	18,198	99.5	100.3	97.7	95.5	92.1
Larynx	1,499	7.7	8.2	8.4	7.3	7.2
Lung and Bronchus	15,963	88.2	88.0	85.1	84.3	81.0
Bones and Joints	244	1.1	1.0	1.5	1.3	1.1
Soft Tissue (Including Heart)	760	4.0	3.7	4.0	3.9	3.9
Skin (Excluding Basal and Squamous)	4,968	22.2	22.9	26.7	29.7	27.1
Melanoma of the Skin	4,424	19.8	19.8	23.5	26.6	24.6

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

Table 1 (continued). Age-adjusted Incidence Rates, Males All Races Combined

Cancer Site	Total Cases	Rates 1999	2000	2001	2002	2003 Prelim.
Breast	269	1.6	1.2	1.5	1.4	1.5
Male Genital System	39,496	201.7	209.5	220.4	222.3	182.3
Prostate	38,049	195.1	202.7	213.2	214.9	175.1
Testis	1,220	5.6	5.5	6.0	6.1	5.8
Penis	179	0.6	1.1	0.9	1.1	1.1
Urinary System	12,359	67.5	66.2	68.6	64.7	64.7
Urinary Bladder (Including in situ)	8,335	46.9	45.8	47.0	43.6	44.2
Kidney and Renal Pelvis	3,747	18.7	18.6	20.2	19.7	19.4
Ureter	178	1.1	1.1	1.1	0.8	0.8
Eye and Orbit	192	0.6	1.2	0.9	1.1	1.0
Brain and Other Nervous System	1,635	7.8	8.6	8.2	7.8	8.8
Brain	1,514	7.2	8.0	7.5	7.4	8.1
Endocrine System	1,260	5.2	6.2	5.9	6.9	6.8
Thyroid	1,066	4.2	5.2	4.6	6.0	5.9
Lymphomas	5,673	29.5	28.1	31.5	28.4	29.6
Hodgkin Lymphoma	751	3.7	3.3	3.9	3.3	4.1
Non-Hodgkin Lymphoma	4,922	25.8	24.8	27.6	25.1	25.5
Myelomas	1,344	6.8	7.8	7.6	7.7	6.1
Leukemias	3,123	17.0	15.3	18.1	16.3	16.2
Lymphocytic Leukemia	1,508	8.2	7.2	9.0	7.6	7.7
Acute Lymphocytic Leukemia	319	1.9	1.1	1.6	2.1	1.3
Chronic Lymphocytic Leukemia	1,059	5.7	5.3	6.5	5.0	6.0
Myeloid and Monocytic Leukemia	1,412	7.2	6.7	8.2	7.5	7.7
Acute Myeloid Leukemia	929	4.8	4.1	5.8	5.2	4.8
Acute Monocytic Leukemia	57	0.4	0.3	0.1	0.2	0.5
Chronic Myeloid Leukemia	386	1.8	2.1	2.0	2.0	2.2
Other Leukemia	203	1.6	1.4	0.9	1.1	0.8
Ill-Defined & Unspecified Sites	3,207	14.0	13.0	*20.2	*19.2	*21.3

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

* Increase in Ill-Defined & Unspecified rates is due to newly reportable ill-defined cases beginning in 2001.

Table 2. Age-adjusted Incidence Rates, Females All Races Combined

Cancer Site	Total Cases	Rates 1999	2000	2001	2002	2003 Prelim.
All Sites	112,380	450.3	451.0	465.9	450.7	441.6
Oral Cavity and Pharynx	1,521	7.1	5.8	6.1	5.9	5.8
Lip	74	0.3	0.2	0.3	0.2	0.4
Tongue	401	1.8	1.5	1.7	1.6	1.7
Salivary Gland	235	0.9	1.0	1.1	1.1	0.8
Floor of Mouth	98	0.4	0.4	0.3	0.5	0.4
Gum and Other Mouth	328	1.7	1.2	1.3	1.0	1.2
Nasopharynx	84	0.4	0.2	0.3	0.5	0.4
Tonsil	126	0.8	0.5	0.5	0.4	0.5
Oropharynx	61	0.3	0.3	0.2	0.2	0.2
Hypopharynx	70	0.3	0.3	0.3	0.3	0.2
Digestive System	21,608	83.0	83.6	84.2	82.3	81.0
Esophagus	634	2.5	2.4	2.5	2.4	2.6
Stomach	1,615	6.5	6.2	5.9	5.7	6.6
Small Intestine	404	1.5	1.3	1.6	1.8	1.9
Colon and Rectum	13,720	52.8	53.4	54.3	52.5	49.3
Colon excluding Rectum	10,379	39.4	39.9	41.4	39.2	37.1
Rectum and Rectosigmoid Junction	3,341	13.4	13.5	12.9	13.3	12.2
Anus, Anal Canal and Anorectum	366	1.3	1.6	1.6	1.5	1.4
Liver and Intrahepatic Bile Duct	776	2.8	3.1	3.2	2.8	3.2
Liver	614	2.1	2.3	2.5	2.3	2.7
Intrahepatic Bile Duct	162	0.7	0.8	0.6	0.4	0.4
Gallbladder	427	1.7	1.6	1.7	1.4	1.7
Pancreas	2,894	11.2	11.8	10.4	10.9	10.8
Respiratory System	14,770	58.6	57.9	59.5	58.8	57.5
Larynx	374	1.7	1.5	1.6	1.6	1.3
Lung and Bronchus	14,101	55.6	55.1	56.8	56.1	55.1
Bones and Joints	205	0.8	1.0	1.0	0.7	1.0
Soft Tissue (Including Heart)	701	2.4	3.2	3.0	3.2	3.0
Skin (Excluding Basal and Squamous)	3,688	12.5	13.8	16.3	17.8	15.9
Melanoma of the Skin	3,399	11.5	12.7	15.1	16.5	14.8
Breast (Invasive)	32,627	140.1	137.5	136.8	129.8	126.4
in situ (not included in All Sites)	8,283	34.1	33.7	34.6	35.2	37.1

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

Table 2 (continued). Age-adjusted Incidence Rates, Females All Races Combined

Cancer Site	Total Cases	Rates 1999	2000	2001	2002	2003 Prelim.
Female Genital System	14,127	59.5	58.4	61.2	56.6	54.9
Cervix Uteri	2,289	10.6	9.9	10.1	9.2	9.4
Corpus and Uterus, NOS	7,014	29.7	28.3	29.8	28.2	27.4
Corpus Uteri	6,768	28.6	27.3	28.8	27.4	26.4
Uterus, NOS	246	1.1	1.0	1.0	0.8	1.0
Ovary	3,849	15.9	16.2	17.0	15.3	14.3
Vagina	176	0.6	0.8	0.8	0.5	0.8
Vulva	623	2.2	2.5	2.5	2.7	2.3
Urinary System	5,654	21.7	21.5	23.0	23.2	21.2
Urinary Bladder (Including in situ)	3,128	11.3	12.8	12.6	12.1	11.3
Kidney and Renal Pelvis	2,372	9.7	8.3	9.8	10.5	9.4
Ureter	110	0.5	0.3	0.4	0.5	0.4
Eye and Orbit	156	0.5	0.7	0.9	0.5	0.6
Brain and Other Nervous System	1,387	6.3	5.7	6.0	5.3	5.9
Brain	1,251	5.7	5.2	5.4	4.8	5.1
Endocrine System	3,531	11.4	14.9	15.9	16.8	18.4
Thyroid	3,363	10.9	14.2	15.0	16.2	17.5
Lymphomas	5,210	21.1	21.4	21.4	20.9	21.0
Hodgkin Lymphoma	689	3.0	3.2	3.2	3.2	3.1
Non-Hodgkin Lymphoma	4,521	18.1	18.3	18.2	17.7	17.9
Myelomas	1,310	4.7	5.5	5.7	4.8	4.6
Leukemias	2,421	9.6	10.0	9.9	9.9	9.4
Lymphocytic Leukemia	1,116	4.3	4.6	4.5	5.0	4.3
Acute Lymphocytic Leukemia	286	1.2	1.5	1.1	1.3	1.6
Chronic Lymphocytic Leukemia	769	2.9	2.8	3.1	3.4	2.5
Myeloid and Monocytic Leukemia	1,123	4.4	4.5	4.9	4.3	4.5
Acute Myeloid Leukemia	772	3.0	3.1	3.5	2.9	3.1
Acute Monocytic Leukemia	43	0.1	0.2	-	0.2	0.2
Chronic Myeloid Leukemia	279	1.2	1.2	1.2	1.0	1.2
Other Leukemia	182	0.9	0.8	0.5	0.6	0.6
Ill-Defined & Unspecified Sites	3,464	10.9	10.1	*14.9	*14.2	*15.0

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.
* Increase in Ill-Defined & Unspecified rates is due to newly reportable ill-defined cases beginning in 2001.
- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 3. Age-adjusted Incidence Rates, White Males

Cancer Site	Total Cases	Rates 1999	2000	2001	2002	2003 Prelim.
All Sites	101,408	622.3	627.7	649.1	636.9	585.4
Oral Cavity and Pharynx	2,376	14.3	14.6	14.0	14.3	14.3
Lip	119	0.7	0.8	0.9	1.0	0.4
Tongue	700	3.8	4.0	4.4	4.3	4.4
Salivary Gland	272	1.5	1.9	1.7	1.6	1.7
Floor of Mouth	157	1.2	0.9	0.7	1.0	0.9
Gum and Other Mouth	306	1.9	1.9	1.8	1.8	1.9
Nasopharynx	133	1.0	0.7	0.7	0.7	0.8
Tonsil	323	1.5	2.1	1.7	1.8	2.3
Oropharynx	96	0.6	0.8	0.3	0.6	0.5
Hypopharynx	210	1.4	1.2	1.5	1.2	1.1
Digestive System	19,785	129.6	125.5	124.7	119.8	116.5
Esophagus	1,353	8.6	8.5	7.9	7.9	8.4
Stomach	2,032	14.5	11.7	12.6	13.1	11.7
Small Intestine	357	2.1	2.1	2.2	2.2	2.2
Colon and Rectum	11,722	79.2	76.7	73.3	70.8	66.4
Colon excluding Rectum	8,093	55.4	53.0	51.1	49.2	46.2
Rectum and Rectosigmoid Junction	3,629	23.8	23.7	22.2	21.6	20.2
Anus, Anal Canal and Anorectum	159	1.1	0.6	1.0	1.1	1.1
Liver and Intrahepatic Bile Duct	1,299	6.6	8.4	8.8	7.6	8.4
Liver	1,162	5.7	7.3	7.9	7.0	7.7
Intrahepatic Bile Duct	137	0.9	1.1	1.0	0.7	0.8
Gallbladder	165	0.8	1.0	1.2	0.8	1.4
Pancreas	2,205	13.4	13.6	14.7	13.4	13.5
Respiratory System	15,591	98.2	99.2	97.2	94.3	91.5
Larynx	1,220	7.3	7.7	7.9	6.9	7.0
Lung and Bronchus	13,692	87.0	87.0	85.0	83.2	80.2
Bones and Joints	203	1.2	1.1	1.7	1.2	1.1
Soft Tissue (Including Heart)	639	4.1	3.8	4.1	4.1	3.7
Skin (Excluding Basal and Squamous)	4,764	25.1	26.0	30.1	33.5	30.4
Melanoma of the Skin	4,324	22.8	22.9	27.1	30.6	27.9

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

Table 3 (continued). Age-adjusted Incidence Rates, White Males

Cancer Site	Total Cases	Rates 1999	2000	2001	2002	2003 Prelim.
Breast	230	1.6	1.3	1.3	1.4	1.5
Male Genital System	32,367	195.0	203.7	210.5	211.7	166.5
Prostate	31,038	187.3	195.9	202.2	202.9	158.2
Testis	1,132	6.7	6.6	7.1	7.4	6.8
Penis	153	0.6	1.0	0.8	1.1	1.1
Urinary System	11,329	71.7	69.8	72.8	68.5	68.1
Urinary Bladder (Including in situ)	7,829	50.9	48.8	50.2	47.1	47.7
Kidney and Renal Pelvis	3,246	18.8	19.0	21.1	20.1	19.2
Ureter	169	1.2	1.2	1.2	0.9	0.8
Eye and Orbit	179	0.7	1.4	1.0	1.1	1.2
Brain and Other Nervous System	1,439	8.1	9.4	8.4	8.3	9.6
Brain	1,340	7.5	8.7	7.8	8.0	8.7
Endocrine System	1,091	5.4	6.4	5.9	7.4	7.3
Thyroid	928	4.5	5.5	4.7	6.4	6.4
Lymphomas	4,886	29.6	29.3	31.9	29.2	30.5
Hodgkin Lymphoma	641	3.8	3.4	4.3	3.7	4.6
Non-Hodgkin Lymphoma	4,245	25.9	26.0	27.6	25.5	25.8
Myelomas	1,067	6.3	7.2	6.9	7.1	5.6
Leukemias	2,713	17.7	16.0	18.7	16.0	16.3
Lymphocytic Leukemia	1,331	8.6	7.7	9.6	7.5	8.0
Acute Lymphocytic Leukemia	265	1.9	1.2	1.8	2.1	1.4
Chronic Lymphocytic Leukemia	946	6.1	5.6	6.8	4.7	6.2
Myeloid and Monocytic Leukemia	1,205	7.4	6.9	8.2	7.4	7.6
Acute Myeloid Leukemia	808	5.1	4.3	5.9	5.1	4.8
Acute Monocytic Leukemia	47	0.4	0.4	-	0.2	0.5
Chronic Myeloid Leukemia	315	1.8	2.1	1.9	2.0	2.1
Other Leukemia	177	1.6	1.4	0.9	1.1	0.7
Ill-Defined & Unspecified Sites	2,749	14.0	12.9	*19.8	*18.8	*21.3

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

* Increase in Ill-Defined & Unspecified rates is due to newly reportable ill-defined cases beginning in 2001.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 4. Age-adjusted Incidence Rates, White Females

Cancer Site	Total Cases	Rates 1999	2000	2001	2002	2003 Prelim.
All Sites	97,203	462.5	463.6	478.8	461.8	449.8
Oral Cavity and Pharynx	1,248	6.9	5.8	6.0	5.7	5.2
Lip	72	0.3	0.3	0.3	0.3	0.4
Tongue	336	1.7	1.5	1.7	1.6	1.6
Salivary Gland	186	0.9	1.0	1.0	1.0	0.7
Floor of Mouth	87	0.4	0.4	0.4	0.5	0.4
Gum and Other Mouth	273	1.8	1.2	1.2	1.1	1.0
Nasopharynx	49	0.2	0.2	0.2	0.4	0.2
Tonsil	107	0.8	0.4	0.5	0.4	0.5
Oropharynx	47	0.3	0.3	0.2	0.1	0.2
Hypopharynx	56	0.3	0.3	0.3	0.3	0.1
Digestive System	18,377	81.8	82.0	82.7	80.0	78.8
Esophagus	515	2.3	2.0	2.4	2.3	2.4
Stomach	1,269	5.9	5.5	5.0	5.1	6.3
Small Intestine	312	1.3	1.3	1.4	1.7	1.6
Colon and Rectum	11,821	52.7	53.4	54.3	51.6	47.7
Colon excluding Rectum	8,942	38.8	40.0	41.1	38.6	35.9
Rectum and Rectosigmoid Junction	2,879	13.8	13.4	13.1	13.0	11.9
Anus, Anal Canal and Anorectum	320	1.4	1.6	1.7	1.5	1.5
Liver and Intrahepatic Bile Duct	630	2.7	2.7	3.1	2.6	3.0
Liver	487	1.9	1.9	2.4	2.1	2.6
Intrahepatic Bile Duct	143	0.8	0.8	0.7	0.5	0.4
Gallbladder	358	1.7	1.5	1.6	1.4	1.6
Pancreas	2,464	11.1	11.5	10.2	10.4	10.8
Respiratory System	13,085	60.2	60.1	61.8	61.1	59.3
Larynx	312	1.6	1.5	1.9	1.5	1.2
Lung and Bronchus	12,506	57.2	57.2	58.8	58.5	57.0
Bones and Joints	172	0.8	1.0	1.0	0.7	1.1
Soft Tissue (Including Heart)	564	2.5	3.0	3.1	3.0	2.8
Skin (Excluding Basal and Squamous)	3,554	14.8	16.4	19.4	20.9	18.4
Melanoma of the Skin	3,299	13.8	15.3	18.2	19.5	17.3
Breast (Invasive)	28,105	146.0	142.1	141.3	133.7	129.6
in situ (not included in All Sites)	7,176	36.6	35.2	36.2	37.8	38.3

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

Table 4 (continued). Age-adjusted Incidence Rates, White Females

Cancer Site	Total Cases	Rates 1999	2000	2001	2002	2003 Prelim.
Female Genital System	12,098	61.3	59.9	63.4	58.3	55.8
Cervix Uteri	1,726	10.2	9.0	9.7	8.5	8.9
Corpus and Uterus, NOS	6,173	31.3	29.9	31.5	29.8	28.3
Corpus Uteri	5,973	30.3	28.9	30.6	29.1	27.2
Uterus, NOS	200	1.0	1.0	0.9	0.7	1.1
Ovary	3,386	16.6	17.0	17.9	16.2	15.0
Vagina	132	0.5	0.7	0.7	0.5	0.6
Vulva	545	2.1	2.5	2.7	2.7	2.4
Urinary System	5,044	22.4	23.0	23.7	24.2	21.8
Urinary Bladder (including in situ)	2,853	11.9	13.9	13.3	12.6	11.9
Kidney and Renal Pelvis	2,059	9.8	8.7	9.8	11.0	9.4
Ureter	105	0.5	0.3	0.5	0.6	0.4
Eye and Orbit	148	0.6	0.9	0.9	0.5	0.7
Brain and Other Nervous System	1,231	6.9	6.2	6.4	5.4	6.8
Brain	1,111	6.3	5.6	5.8	4.9	6.0
Endocrine System	2,970	12.4	15.6	16.9	18.1	19.3
Thyroid	2,837	11.8	14.8	16.0	17.5	18.6
Lymphomas	4,587	21.7	22.6	22.5	22.3	21.7
Hodgkin Lymphoma	594	3.2	3.5	3.6	3.9	3.2
Non-Hodgkin Lymphoma	3,993	18.4	19.1	18.9	18.4	18.5
Myelomas	996	4.0	4.6	5.3	4.2	4.1
Leukemias	2,090	10.0	10.3	10.3	9.7	9.6
Lymphocytic Leukemia	971	4.5	4.8	4.8	4.9	4.5
Acute Lymphocytic Leukemia	240	1.4	1.6	1.3	1.3	1.8
Chronic Lymphocytic Leukemia	680	3.0	3.0	3.2	3.3	2.5
Myeloid and Monocytic Leukemia	970	4.6	4.7	5.1	4.2	4.5
Acute Myeloid Leukemia	679	3.2	3.2	3.7	3.0	3.1
Acute Monocytic Leukemia	37	-	0.3	-	0.2	0.2
Chronic Myeloid Leukemia	230	1.2	1.2	1.1	0.8	1.2
Other Leukemia	149	0.9	0.8	0.5	0.6	0.5
Ill-Defined & Unspecified Sites	2,934	10.2	10.1	*14.3	*13.8	*14.8

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

* Increase in Ill-Defined & Unspecified rates is due to newly reportable ill-defined cases beginning in 2001.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 5. Age-adjusted Incidence Rates, Black Males

Cancer Site	Total Cases	Rates 1999	2000	2001	2002	2003 Prelim.
All Sites	13,232	711.3	707.9	735.3	684.9	662.8
Oral Cavity and Pharynx	396	16.1	23.3	19.5	18.6	13.7
Lip	-	-	-	-	-	-
Tongue	105	5.4	5.5	4.6	4.8	4.3
Salivary Gland	28	-	0.9	1.8	1.5	-
Floor of Mouth	33	1.2	-	2.9	1.4	-
Gum and Other Mouth	48	1.3	3.8	1.9	2.4	1.8
Nasopharynx	28	-	1.6	1.0	2.0	0.9
Tonsil	61	2.4	2.9	2.7	2.7	2.2
Oropharynx	18	-	2.3	-	1.2	-
Hypopharynx	50	2.1	4.2	2.5	1.4	1.9
Digestive System	2,651	151.4	147.9	145.3	144.8	146.5
Esophagus	248	12.5	14.9	15.2	9.9	13.0
Stomach	340	22.8	18.5	20.7	19.6	17.0
Small Intestine	62	3.6	2.6	3.0	4.0	2.5
Colon and Rectum	1,387	77.7	81.3	75.1	78.4	82.4
Colon excluding Rectum	1,028	59.4	58.7	56.3	60.4	64.8
Rectum and Rectosigmoid Junction	359	18.2	22.5	18.8	18.0	17.6
Anus, Anal Canal and Anorectum	46	2.1	1.1	1.9	2.2	1.6
Liver and Intrahepatic Bile Duct	238	9.9	10.4	15.4	11.2	11.7
Liver	228	8.7	10.2	14.8	11.0	11.0
Intrahepatic Bile Duct	10	-	-	-	-	-
Gallbladder	14	-	-	-	-	-
Pancreas	267	19.9	16.3	11.4	14.3	15.3
Respiratory System	2,196	125.2	123.1	121.6	116.1	107.2
Larynx	242	12.2	14.6	13.4	11.0	9.2
Lung and Bronchus	1,910	111.0	107.1	103.8	103.3	96.6
Bones and Joints	21	-	-	-	1.2	1.0
Soft Tissue (Including Heart)	95	4.3	4.1	3.5	3.2	5.1
Skin (Excluding Basal and Squamous)	91	3.4	3.0	4.6	3.8	3.1
Melanoma of the Skin	16	-	-	1.3	-	-

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.
- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 5 (continued). Age-adjusted Incidence Rates, Black Males

Cancer Site	Total Cases	Rates 1999	2000	2001	2002	2003 Prelim.
Breast	33	2.1	-	2.6	1.7	1.4
Male Genital System	5,433	294.4	294.8	312.5	282.7	270.8
Prostate	5,364	292.7	291.6	309.1	280.8	267.5
Testis	50	1.2	1.3	2.0	1.7	2.1
Penis	16	-	1.7	1.2	-	-
Urinary System	707	39.4	42.7	38.5	34.3	36.8
Urinary Bladder (Including in situ)	315	17.9	24.4	22.1	14.6	14.3
Kidney and Renal Pelvis	377	20.4	17.5	15.9	18.8	21.7
Ureter	5	-	-	-	-	-
Eye and Orbit	7	-	-	-	-	-
Brain and Other Nervous System	113	5.5	4.1	5.9	3.1	4.3
Brain	102	5.4	3.9	4.8	2.6	4.2
Endocrine System	97	3.8	6.3	3.4	2.8	4.1
Thyroid	72	2.5	4.0	2.4	2.7	3.4
Lymphomas	542	26.4	20.0	24.3	22.6	21.1
Hodgkin Lymphoma	77	5.2	3.2	2.5	2.2	1.9
Non-Hodgkin Lymphoma	465	21.2	16.8	21.8	20.5	19.3
Myelomas	238	12.4	14.3	15.4	13.5	11.3
Leukemias	251	10.5	8.6	13.9	13.9	14.0
Lymphocytic Leukemia	104	4.4	3.1	5.0	8.3	3.9
Acute Lymphocytic Leukemia	35	1.2	-	0.7	2.5	1.1
Chronic Lymphocytic Leukemia	65	2.7	2.6	4.2	5.7	2.9
Myeloid and Monocytic Leukemia	129	4.8	4.8	8.5	5.4	8.6
Acute Myeloid Leukemia	79	3.0	2.2	5.4	4.6	4.8
Acute Monocytic Leukemia	6	-	-	-	-	-
Chronic Myeloid Leukemia	42	-	2.5	2.6	-	3.3
Other Leukemia	18	1.3	-	-	-	1.5
Ill-Defined & Unspecified Sites	361	15.5	14.7	*23.8	*22.3	*22.3

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

* Increase in Ill-Defined & Unspecified rates is due to newly reportable ill-defined cases beginning in 2001.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 6. Age-adjusted Incidence Rates, Black Females

Cancer Site	Total Cases	Rates 1999	2000	2001	2002	2003 Prelim.
All Sites	11,346	405.2	411.5	407.3	413.2	398.8
Oral Cavity and Pharynx	184	8.1	4.7	4.5	6.5	8.4
Lip	-	-	-	-	-	-
Tongue	44	2.5	0.9	1.3	1.2	1.5
Salivary Gland	28	-	-	1.0	1.4	1.1
Floor of Mouth	11	-	-	-	-	-
Gum and Other Mouth	36	-	1.3	0.9	1.2	2.5
Nasopharynx	13	-	-	-	-	0.8
Tonsil	19	1.0	-	-	-	0.8
Oropharynx	13	0.9	-	-	-	-
Hypopharynx	11	-	-	-	-	-
Digestive System	2,513	93.5	94.7	96.4	96.8	92.0
Esophagus	103	3.6	4.7	3.0	3.2	4.0
Stomach	235	8.9	9.9	10.7	8.2	7.5
Small Intestine	77	3.4	0.9	3.1	2.5	4.0
Colon and Rectum	1,512	55.9	55.6	58.4	58.3	55.2
Colon excluding Rectum	1,181	44.8	42.4	46.8	44.3	44.2
Rectum and Rectosigmoid Junction	331	11.1	13.2	11.6	14.0	11.0
Anus, Anal Canal and Anorectum	33	-	0.9	1.1	1.2	1.7
Liver and Intrahepatic Bile Duct	94	3.5	3.9	3.6	2.5	4.0
Liver	82	3.3	2.8	3.4	2.3	3.4
Intrahepatic Bile Duct	12	-	1.1	-	-	-
Gallbladder	48	1.6	2.1	1.9	1.0	2.7
Pancreas	353	14.4	15.3	12.2	16.3	11.2
Respiratory System	1,460	54.4	52.5	53.8	54.7	53.1
Larynx	58	2.5	2.0	-	2.9	2.2
Lung and Bronchus	1,382	51.4	49.5	52.5	51.3	50.1
Bones and Joints	16	0.8	-	-	-	0.9
Soft Tissue (Including Heart)	109	2.1	4.4	3.5	4.2	4.1
Skin (Excluding Basal and Squamous)	52	1.4	1.3	1.5	1.6	3.1
Melanoma of the Skin	25	-	1.0	-	0.9	1.5
Breast (Invasive)	3,261	110.8	122.7	113.6	113.3	106.6
in situ (not included in All Sites)	711	22.9	22.4	25.8	22.9	27.5

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.
- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 6 (continued). Age-adjusted Incidence Rates, Black Females

Cancer Site	Total Cases	Rates 1999	2000	2001	2002	2003 Prelim.
Female Genital System	1,520	54.7	54.9	52.7	52.1	51.8
Cervix Uteri	448	16.3	17.9	13.6	13.9	13.3
Corpus and Uterus, NOS	634	22.5	21.0	24.4	22.8	23.4
Corpus Uteri	591	20.0	19.7	22.6	20.8	23.0
Uterus, NOS	43	2.4	1.3	1.8	1.9	-
Ovary	309	11.6	11.4	10.7	10.6	10.6
Vagina	35	0.9	1.6	1.5	-	1.6
Vulva	66	2.6	2.1	1.8	3.1	2.1
Urinary System	471	17.5	14.7	18.4	20.4	16.9
Urinary Bladder (Including in situ)	209	7.1	7.4	8.0	11.0	7.7
Kidney and Renal Pelvis	243	9.5	6.7	9.6	8.8	8.5
Ureter	-	-	-	-	-	-
Eye and Orbit	-	-	-	-	-	-
Brain and Other Nervous System	99	3.5	2.9	3.8	4.3	2.6
Brain	91	3.3	2.9	3.6	3.8	2.2
Endocrine System	279	5.2	9.7	9.4	8.9	11.9
Thyroid	259	5.0	9.6	8.7	8.1	10.6
Lymphomas	452	18.0	15.2	13.9	13.3	15.5
Hodgkin Lymphoma	79	2.6	2.7	2.4	1.2	3.0
Non-Hodgkin Lymphoma	373	15.4	12.5	11.5	12.2	12.5
Myelomas	276	10.6	13.3	8.7	10.5	8.9
Leukemias	217	7.0	8.7	7.6	7.9	6.8
Lymphocytic Leukemia	85	2.6	3.4	2.7	3.9	2.3
Acute Lymphocytic Leukemia	24	0.7	-	-	1.0	-
Chronic Lymphocytic Leukemia	56	1.3	2.5	1.9	2.9	1.8
Myeloid and Monocytic Leukemia	106	3.9	3.5	3.6	3.4	3.8
Acute Myeloid Leukemia	61	2.0	2.3	1.8	1.7	2.7
Acute Monocytic Leukemia	6	-	-	-	-	-
Chronic Myeloid Leukemia	35	1.1	1.0	1.9	1.3	0.8
Other Leukemia	26	-	1.8	1.3	-	-
Ill-Defined & Unspecified Sites	435	17.7	11.6	*18.9	*18.2	*16.3

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.
* Increase in Ill-Defined & Unspecified rates is due to newly reportable ill-defined cases beginning in 2001.
- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 7. Age-adjusted Incidence Rates, Hispanic Males and Females 1999-2003 Combined

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
All Sites	539.6	7,276	358.5	6,902
Oral Cavity and Pharynx	12.6	201	4.5	84
Lip	-	-	-	-
Tongue	3.5	59	1.2	24
Salivary Gland	0.6	10	0.7	14
Floor of Mouth	0.6	10	-	-
Gum and Other Mouth	2.1	29	0.8	14
Nasopharynx	0.8	14	0.3	7
Tonsil	1.8	34	0.5	9
Oropharynx	0.8	12	-	-
Hypopharynx	1.6	25	-	-
Digestive System	114.8	1,529	83.7	1,387
Esophagus	6.3	85	2.7	38
Stomach	19.5	272	10.0	167
Small Intestine	2.1	27	1.5	28
Colon and Rectum	58.4	756	45.3	757
Colon excluding Rectum	40.5	504	32.3	533
Rectum and Rectosigmoid Junction	17.9	252	13.1	224
Anus, Anal Canal and Anorectum	0.5	10	1.6	32
Liver and Intrahepatic Bile Duct	12.7	183	4.9	79
Liver	11.7	172	3.7	60
Intrahepatic Bile Duct	1.0	11	1.2	19
Gallbladder	1.4	21	3.6	58
Pancreas	11.6	144	10.8	173
Respiratory System	66.5	840	27.8	467
Larynx	6.7	102	0.7	15
Lung and Bronchus	57.6	704	26.4	438
Bones and Joints	1.3	34	1.3	34
Soft Tissue (Including Heart)	3.0	66	2.8	66
Skin (Excluding Basal and Squamous)	6.8	122	4.2	94
Melanoma of the Skin	4.5	74	3.4	77
Breast (Invasive)	0.4	8	100.2	2,042
in situ (not included in All Sites)	-	-	23.4	496

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

** Non-applicable gender

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 7 (continued). Age-adjusted Incidence Rates, Hispanic Males and Females 1999-2003 Combined

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
Female Genital System	**	**	51.6	1,078
Cervix Uteri	**	**	15.5	381
Corpus and Uterus, NOS	**	**	21.2	402
Corpus Uteri	**	**	20.3	386
Uterus, NOS	**	**	0.9	16
Ovary	**	**	11.0	224
Vagina	**	**	0.7	14
Vulva	**	**	2.6	42
Male Genital System	206.6	2,628	**	**
Prostate	200.9	2,459	**	**
Testis	3.7	135	**	**
Penis	1.8	32	**	**
Urinary System	47.5	572	16.9	295
Urinary Bladder (Including in situ)	31.9	347	8.7	137
Kidney and Renal Pelvis	14.0	209	8.0	153
Ureter	0.7	7	-	-
Eye and Orbit	0.9	14	0.4	8
Brain and Other Nervous System	6.9	133	5.3	125
Brain	6.7	125	4.4	106
Endocrine System	4.6	94	14.1	363
Thyroid	3.7	77	13.3	347
Lymphomas	29.1	484	18.3	368
Hodgkin Lymphoma	3.9	97	2.5	69
Non-Hodgkin Lymphoma	25.2	387	15.8	299
Myelomas	9.5	114	5.5	88
Leukemias	14.4	239	9.3	196
Lymphocytic Leukemia	5.6	104	4.0	90
Acute Lymphocytic Leukemia	1.6	51	1.9	55
Chronic Lymphocytic Leukemia	3.6	41	1.9	29
Myeloid and Monocytic Leukemia	7.4	117	4.6	93
Acute Myeloid Leukemia	4.2	70	3.5	70
Acute Monocytic Leukemia	-	-	-	-
Chronic Myeloid Leukemia	2.6	40	0.8	17
Other Leukemia	1.4	18	0.7	13
Ill-Defined & Unspecified Sites	14.9	198	12.7	207

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.
** Non-applicable gender.
- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 8. Comparative Incidence Rates, New Jersey and U.S., 1998-2002
Males

Cancer Site	New Jersey 1998-2002			United States 1998-2002		
Population:	All Races Combined	White	Black	All Races Combined	White	Black
All Sites	629.0	642.6	702.6	561.4	553.7	641.5
Colorectal	75.5	75.6	78.3	65.9	65.5	70.2
Lung	87.6	86.6	109.7	90.1	89.3	112.2
Prostate	201.2	192.0	283.2	163.8	155.0	242.6
Melanoma	21.8	25.0	0.7	19.9	21.7	1.1
Non-Hodgkin Lymphoma	25.8	26.2	20.5	22.6	23.0	16.7

Source: NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

Table 9. Comparative Incidence Rates, New Jersey and U.S., 1998-2002
Females

Cancer Site	New Jersey 1998-2002			United States 1998-2002		
Population:	All Races Combined	White	Black	All Races Combined	White	Black
All Sites	450.2	461.8	408.8	418.2	423.3	384.5
Colorectal	53.7	53.5	57.3	47.9	47.2	53.8
Lung	55.4	57.3	51.9	54.6	55.9	51.2
Breast (invasive)	136.1	140.7	115.2	131.0	133.5	111.8
Melanoma	13.4	16.0	0.8	12.8	14.3	0.9
Non-Hodgkin Lymphoma	18.1	18.8	13.1	16.0	16.4	11.0

Source: NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

Page intentionally blank

Table 10. Age-adjusted Mortality Rates, Males All Races Combined

Cancer Site	Total Cases	Rates 1999	2000	2001	2002
All Sites	35,574	258.2	249.0	246.6	236.4
Oral Cavity and Pharynx	593	4.0	3.6	4.3	3.6
Lip	-	-	-	-	-
Tongue	159	1.2	1.0	1.0	0.9
Salivary Gland	59	0.3	0.3	0.4	0.6
Floor of Mouth	16	-	0.1	-	-
Gum and Other Mouth	57	0.4	0.2	0.4	0.4
Nasopharynx	53	0.2	0.5	0.5	-
Tonsil	47	0.4	0.1	0.5	0.2
Oropharynx	54	0.4	0.3	0.4	0.2
Hypopharynx	25	0.2	0.2	0.2	-
Digestive System	9,474	69.0	66.5	64.1	62.5
Esophagus	1,179	7.9	8.2	7.9	7.4
Stomach	1,113	8.5	7.4	7.4	7.5
Small Intestine	83	0.7	0.5	0.5	0.5
Colon and Rectum	3,898	28.7	28.4	26.4	26.4
Colon excluding Rectum	3,272	24.6	23.5	22.3	22.0
Rectum and Rectosigmoid Junction	626	4.0	4.9	4.1	4.5
Anus	16	-	-	-	0.1
Liver and Intrahepatic Bile Duct	1,048	6.7	7.6	7.4	6.5
Liver	872	5.4	6.1	6.2	5.5
Intrahepatic Bile Duct	176	1.2	1.5	1.2	1.0
Gallbladder	82	0.7	0.4	0.7	0.5
Pancreas	1,859	13.8	12.7	12.5	12.3
Respiratory System	10,666	75.6	73.2	73.6	67.9
Larynx	357	2.7	1.9	2.5	2.4
Lung and Bronchus	10,221	72.2	70.8	70.5	64.9
Bones and Joints	62	0.5	0.4	0.5	0.2
Soft Tissue (Including Heart)	216	1.6	1.5	1.3	1.3
Skin (Excluding Basal and Squamous)	765	5.2	5.1	5.2	5.2
Melanoma of the Skin	599	4.0	4.0	4.1	4.0

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 10 (continued). Age-adjusted Mortality Rates, Males All Races Combined

Cancer Site	Total Cases	Rates 1999	2000	2001	2002
Breast	68	0.4	0.5	0.4	0.6
Male Genital System	3,863	30.9	30.0	30.5	26.4
Prostate	3,799	30.5	29.5	30.1	26.0
Testis	36	0.2	0.2	0.2	0.2
Penis	25	0.2	0.2	0.1	-
Urinary System	2,133	15.7	15.5	14.4	15.6
Urinary Bladder	1,197	9.7	9.3	8.2	8.2
Kidney and Renal Pelvis	884	5.6	5.8	5.9	7.0
Ureter	25	0.2	0.2	0.2	0.2
Eye	7	-	-	-	-
Brain and Other Nervous System	717	4.4	4.9	4.6	4.5
Endocrine System	142	0.9	1.0	1.0	0.9
Thyroid	84	0.6	0.5	0.7	0.4
Lymphomas	1,634	11.7	11.6	10.5	11.1
Hodgkin Lymphoma	93	0.7	0.6	0.5	0.6
Non-Hodgkin Lymphoma	1,541	11.0	11.0	10.0	10.5
Multiple Myeloma	662	4.1	4.6	5.1	4.6
Leukemias	1,447	11.3	9.9	8.6	10.5
Lymphocytic Leukemia	410	3.5	2.7	2.3	3.2
Acute Lymphocytic Leukemia	91	0.7	0.5	0.5	0.7
Chronic Lymphocytic Leukemia	288	2.6	2.0	1.6	2.3
Myeloid and Monocytic Leukemia	625	4.5	4.0	3.6	4.8
Acute Myeloid Leukemia	470	3.4	3.0	2.6	3.7
Acute Monocytic Leukemia	5	-	-	-	-
Chronic Myeloid Leukemia	119	0.9	0.9	0.7	0.8
Other Leukemia	412	3.4	3.2	2.7	2.5
Ill-Defined & Unspecified Sites	3,125	22.7	20.6	22.3	21.5

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 11. Age-adjusted Mortality Rates, Females All Races Combined

Cancer Site	Total Cases	Rates 1999	2000	2001	2002
All Sites	36,666	178.7	178.0	176.7	172.1
Oral Cavity and Pharynx	308	1.5	1.3	1.6	1.5
Lip	-	-	-	-	-
Tongue	88	0.3	0.4	0.6	0.4
Salivary Gland	30	0.2	0.1	0.1	0.1
Floor of Mouth	-	-	-	-	0.0
Gum and Other Mouth	63	0.4	0.2	0.3	0.3
Nasopharynx	28	0.1	-	0.1	0.2
Tonsil	18	0.1	0.1	-	-
Oropharynx	20	-	0.1	0.1	0.1
Hypopharynx	8	-	-	-	-
Digestive System	8,686	42.1	40.5	40.7	38.8
Esophagus	400	2.0	1.9	1.8	2.0
Stomach	803	4.5	3.7	3.5	3.5
Small Intestine	61	0.3	0.3	0.3	0.3
Colon and Rectum	4,141	19.8	19.1	19.6	17.9
Colon excluding Rectum	3,592	17.2	16.4	17.1	15.4
Rectum and Rectosigmoid Junction	549	2.6	2.7	2.5	2.5
Anus	25	0.2	-	0.1	0.1
Liver and Intrahepatic Bile Duct	594	2.8	2.9	3.1	2.5
Liver	395	1.9	1.8	2.2	1.6
Intrahepatic Bile Duct	199	1.0	1.1	0.9	0.9
Gallbladder	212	1.2	1.0	0.9	0.9
Pancreas	2,189	10.1	10.3	10.3	10.4
Respiratory System	8,473	40.6	42.0	41.5	41.5
Larynx	113	0.6	0.5	0.6	0.5
Lung and Bronchus	8,320	39.7	41.3	40.6	40.8
Bones and Joints	55	0.3	0.3	0.3	0.2
Soft Tissue (Including Heart)	262	1.3	1.5	1.3	1.3
Skin (Excluding Basal and Squamous)	426	2.1	1.9	2.1	2.0
Melanoma of the Skin	349	1.8	1.5	1.8	1.7
Breast	5,946	28.8	30.9	28.7	28.4

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 11 (continued). Age-adjusted Mortality Rates, Females All Races Combined

Cancer Site	Total Cases	Rates 1999	2000	2001	2002
Female Genital System	3,823	18.2	18.6	19.5	18.7
Cervix Uteri	550	3.2	2.8	3.1	2.4
Corpus and Uterus, NOS	1,055	4.5	5.1	5.5	5.3
Corpus Uteri	439	1.8	2.1	2.1	2.5
Uterus, NOS	616	2.7	3.0	3.5	2.7
Ovary	2,002	9.5	9.6	10.0	10.1
Vagina	36	0.3	0.1	0.2	0.1
Vulva	126	0.5	0.8	0.5	0.5
Urinary System	1,202	5.3	5.6	5.8	5.9
Urinary Bladder	601	2.5	2.6	2.9	2.8
Kidney and Renal Pelvis	566	2.6	2.8	2.8	2.8
Ureter	21	0.1	0.1	-	0.2
Eye	15	-	-	-	0.1
Brain and Other Nervous System	620	3.8	3.0	3.0	2.9
Endocrine System	150	0.7	0.8	0.8	0.6
Thyroid	108	0.6	0.5	0.6	0.4
Lymphomas	1,542	7.8	7.4	7.3	6.8
Hodgkin Lymphoma	97	0.5	0.6	0.5	0.5
Non-Hodgkin Lymphoma	1,445	7.3	6.8	6.8	6.3
Multiple Myeloma	713	3.3	3.5	3.5	3.1
Leukemias	1,230	6.2	5.5	5.8	6.1
Lymphocytic Leukemia	335	1.8	1.3	1.5	1.6
Acute Lymphocytic Leukemia	59	0.3	0.3	0.3	0.4
Chronic Lymphocytic Leukemia	253	1.3	1.0	1.1	1.1
Myeloid and Monocytic Leukemia	517	2.5	2.5	2.6	2.6
Acute Myeloid Leukemia	398	1.9	1.8	1.9	2.2
Acute Monocytic Leukemia	7	-	-	-	-
Chronic Myeloid Leukemia	92	0.5	0.6	0.5	0.3
Other Leukemia	378	1.9	1.6	1.6	1.8
Ill-Defined & Unspecified Sites	3,215	16.7	15.1	14.7	14.3

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 12. Age-adjusted Mortality Rates, White Males

Cancer Site	Total Cases	Rates 1999	2000	2001	2002
All Sites	30,557	254.1	244.3	242.8	234.0
Oral Cavity and Pharynx	441	3.3	3.0	4.0	3.2
Lip	-	-	-	-	-
Tongue	124	1.0	0.8	1.1	0.8
Salivary Gland	51	0.3	0.3	0.3	0.6
Floor of Mouth	11	-	-	-	-
Gum and Other Mouth	47	0.4	0.2	0.4	0.4
Nasopharynx	35	0.2	0.4	0.4	-
Tonsil	32	0.3	0.1	0.4	0.2
Oropharynx	34	0.2	0.2	0.4	0.2
Hypopharynx	16	-	-	0.2	-
Digestive System	8,035	66.6	65.0	62.8	61.1
Esophagus	996	7.5	8.2	7.5	7.5
Stomach	895	7.8	7.1	6.7	6.8
Small Intestine	66	0.7	0.4	0.5	0.5
Colon and Rectum	3,394	28.8	27.9	26.4	26.4
Colon excluding Rectum	2,835	25.0	22.7	22.2	21.6
Rectum and Rectosigmoid Junction	559	3.8	5.2	4.1	4.7
Anus	14	-	-	-	0.2
Liver and Intrahepatic Bile Duct	827	6.1	6.9	6.8	6.0
Liver	671	4.9	5.5	5.7	4.9
Intrahepatic Bile Duct	156	1.2	1.5	1.2	1.1
Gallbladder	74	0.8	0.4	0.7	0.4
Pancreas	1,600	13.0	12.7	12.7	12.4
Respiratory System	9,154	75.2	71.7	72.1	67.3
Larynx	271	2.6	1.6	2.1	2.1
Lung and Bronchus	8,805	71.8	69.7	69.4	64.6
Bones and Joints	56	0.6	0.5	0.5	0.2
Soft Tissue (Including Heart)	187	1.7	1.6	1.3	1.2
Skin (Excluding Basal and Squamous)	742	5.9	5.5	5.9	6.0
Melanoma of the Skin	592	4.5	4.4	4.8	4.6

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 12 (continued). Age-adjusted Mortality Rates, White Males

Cancer Site	Total Cases	Rates 1999	2000	2001	2002
Breast	59	0.4	0.4	0.5	0.5
Male Genital System	3,151	28.9	27.0	27.6	24.2
Prostate	3,092	28.4	26.5	27.2	23.8
Testis	34	0.2	0.3	0.2	0.3
Penis	23	0.2	0.2	0.1	-
Urinary System	1,943	15.9	16.1	14.9	16.4
Urinary Bladder	1,115	10.0	9.7	8.6	8.8
Kidney and Renal Pelvis	783	5.5	6.1	6.0	7.2
Ureter	24	0.2	0.2	-	0.2
Eye	7	-	-	-	-
Brain and Other Nervous System	660	4.7	5.4	5.1	4.8
Endocrine System	115	0.8	0.9	1.1	0.7
Thyroid	74	0.6	0.6	0.7	0.4
Lymphomas	1,453	11.8	12.0	11.0	11.3
Hodgkin Lymphoma	81	0.6	0.7	0.6	0.7
Non-Hodgkin Lymphoma	1,372	11.2	11.3	10.4	10.7
Multiple Myeloma	550	3.9	4.4	4.8	4.5
Leukemias	1,287	11.6	10.2	8.9	10.7
Lymphocytic Leukemia	370	3.6	2.9	2.4	3.3
Acute Lymphocytic Leukemia	79	0.7	0.5	0.5	0.8
Chronic Lymphocytic Leukemia	264	2.7	2.1	1.6	2.3
Myeloid and Monocytic Leukemia	545	4.4	4.0	3.8	4.9
Acute Myeloid Leukemia	418	3.4	3.0	2.7	4.0
Acute Monocytic Leukemia	-	-	-	-	-
Chronic Myeloid Leukemia	94	0.8	0.8	0.8	0.6
Other Leukemia	372	3.6	3.3	2.7	2.5
Ill-Defined and Unspecified Sites	2,717	22.6	20.3	22.2	21.7

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 13. Age-adjusted Mortality Rates, White Females

Cancer Site	Total Cases	Rates 1999	2000	2001	2002
All Sites	32,000	179.5	179.0	178.1	173.1
Oral Cavity and Pharynx	255	1.3	1.3	1.6	1.4
Lip	-	-	-	-	-
Tongue	73	0.3	0.4	0.6	0.4
Salivary Gland	30	0.2	0.2	0.2	0.1
Floor of Mouth	-	-	-	-	-
Gum and Other Mouth	57	0.4	0.2	0.3	0.3
Nasopharynx	15	-	-	-	0.1
Tonsil	12	-	0.1	-	-
Oropharynx	19	-	0.1	0.1	0.1
Hypopharynx	6	-	-	-	-
Digestive System	7,496	41.4	40.0	39.1	38.3
Esophagus	329	1.8	1.8	1.5	2.0
Stomach	640	3.9	3.5	2.9	3.3
Small Intestine	51	0.3	0.2	0.3	0.3
Colon and Rectum	3,647	19.8	19.1	19.5	17.8
Colon excluding Rectum	3,151	17.2	16.2	17.0	15.2
Rectum and Rectosigmoid Junction	496	2.6	2.9	2.5	2.6
Anus	24	0.2	-	0.1	0.1
Liver and Intrahepatic Bile Duct	494	2.8	2.7	2.7	2.5
Liver	325	1.7	1.7	1.9	1.6
Intrahepatic Bile Duct	169	1.1	1.0	0.8	0.9
Gallbladder	177	1.1	1.0	0.9	0.9
Pancreas	1,901	10.1	10.3	10.1	10.2
Respiratory System	7,524	41.4	43.3	42.9	42.6
Larynx	98	0.6	0.5	0.7	0.5
Lung and Bronchus	7,390	40.5	42.7	41.9	42.0
Bones and Joints	48	0.3	0.3	0.3	0.3
Soft Tissue (Including Heart)	216	1.3	1.5	1.2	1.1
Skin (Excluding Basal and Squamous)	407	2.4	2.0	2.4	2.2
Melanoma of the Skin	337	2.1	1.6	2.1	1.9
Breast	5,091	29.0	30.7	28.7	28.1

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 13 (continued). Age-adjusted Mortality Rates, White Females

Cancer Site	Total Cases	Rates 1999	2000	2001	2002
Female Genital System	3,271	18.0	18.4	20.0	18.4
Cervix Uteri	404	2.6	2.4	3.1	2.0
Corpus and Uterus, NOS	887	4.3	4.8	5.7	5.0
Corpus Uteri	384	1.8	2.0	2.3	2.5
Uterus, NOS	503	2.5	2.8	3.4	2.5
Ovary	1,784	10.0	9.9	10.3	10.4
Vagina	32	0.3	-	0.2	0.1
Vulva	116	0.5	0.8	0.5	0.6
Urinary System	1,081	5.5	5.6	6.0	6.0
Urinary Bladder	539	2.6	2.7	2.8	2.8
Kidney and Renal Pelvis	510	2.8	2.8	3.0	3.0
Ureter	19	-	0.1	-	0.2
Eye	14	-	-	-	0.1
Brain and Other Nervous System	572	4.1	3.3	3.3	3.2
Endocrine System	132	0.7	0.9	0.8	0.7
Thyroid	97	0.6	0.6	0.6	0.4
Lymphomas	1,412	8.1	7.8	7.7	7.2
Hodgkin Lymphoma	91	0.5	0.6	0.6	0.6
Non-Hodgkin Lymphoma	1,321	7.6	7.2	7.1	6.6
Multiple Myeloma	579	2.9	3.3	3.2	2.8
Leukemias	1,113	6.5	5.6	6.1	6.4
Lymphocytic Leukemia	312	1.9	1.4	1.7	1.7
Acute Lymphocytic Leukemia	55	0.4	0.3	0.4	0.4
Chronic Lymphocytic Leukemia	236	1.4	0.9	1.1	1.2
Myeloid and Monocytic Leukemia	462	2.6	2.5	2.8	2.7
Acute Myeloid Leukemia	360	2.0	1.8	2.1	2.3
Acute Monocytic Leukemia	6	-	-	-	-
Chronic Myeloid Leukemia	80	0.4	0.6	0.5	0.3
Other Leukemia	339	1.9	1.7	1.7	1.9
Ill-Defined & Unspecified Sites	2,789	16.6	14.8	14.7	14.3

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 14. Age-adjusted Mortality Rates, Black Males

Cancer Site	Total Cases	Rates 1999	2000	2001	2002
All Sites	4,428	336.0	346.6	329.8	297.3
Oral Cavity and Pharynx	134	10.5	9.5	7.3	6.8
Lip	-	-	-	-	-
Tongue	34	2.7	3.8	-	1.9
Salivary Gland	6	-	-	-	-
Floor of Mouth	-	-	-	-	-
Gum and Other Mouth	10	-	-	-	-
Nasopharynx	11	-	1.6	-	-
Tonsil	14	-	-	1.2	-
Oropharynx	19	2.0	-	-	-
Hypopharynx	9	-	-	-	-
Digestive System	1,214	91.4	90.2	84.4	77.4
Esophagus	168	13.6	11.0	12.8	8.7
Stomach	179	13.7	12.6	13.4	15.0
Small Intestine	15	-	2.1	-	-
Colon and Rectum	451	31.8	37.0	31.9	28.5
Colon excluding Rectum	395	24.1	35.0	29.0	26.0
Rectum and Rectosigmoid Junction	56	7.6	2.0	2.9	2.6
Anus	-	-	-	-	-
Liver and Intrahepatic Bile Duct	155	8.1	9.8	12.4	8.2
Liver	142	7.6	8.9	11.3	7.8
Intrahepatic Bile Duct	13	-	-	1.0	-
Gallbladder	-	-	-	-	-
Pancreas	217	20.2	15.9	12.1	13.1
Respiratory System	1,372	96.6	102.6	102.0	86.0
Larynx	76	4.3	4.8	7.0	5.4
Lung and Bronchus	1,287	91.8	96.9	95.0	79.9
Bones and Joints	5	-	-	-	-
Soft Tissue (Including Heart)	25	1.2	1.2	1.6	1.7
Skin (Excluding Basal and Squamous)	19	-	1.9	-	-
Melanoma of the Skin	6	-	-	-	-

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 14 (continued). Age-adjusted Mortality Rates, Black Males

Cancer Site	Total Cases	Rates 1999	2000	2001	2002
Breast	8	-	-	-	-
Male Genital System	676	59.9	70.9	69.5	58.1
Prostate	673	59.5	70.4	69.5	58.1
Testis	-	-	-	-	-
Penis	-	-	-	-	-
Urinary System	167	17.9	11.7	10.9	11.4
Urinary Bladder	73	9.3	6.8	4.8	4.3
Kidney and Renal Pelvis	87	8.4	3.8	5.9	6.7
Ureter	-	-	-	-	-
Eye	-	-	-	-	-
Brain and Other Nervous System	40	2.7	2.3	1.5	2.3
Endocrine System	21	1.2	1.0	-	1.5
Thyroid	8	-	-	-	-
Lymphomas	155	10.4	10.1	6.8	10.3
Hodgkin Lymphoma	8	1.4	-	-	-
Non-Hodgkin Lymphoma	147	9.0	9.8	6.7	10.3
Multiple Myeloma	102	6.2	7.2	8.9	6.1
Leukemias	128	8.8	8.5	7.0	10.6
Lymphocytic Leukemia	36	3.3	1.4	2.0	3.5
Acute Lymphocytic Leukemia	9	-	-	-	-
Chronic Lymphocytic Leukemia	23	2.3	-	1.4	2.7
Myeloid and Monocytic Leukemia	64	5.2	4.7	2.7	4.7
Acute Myeloid Leukemia	42	3.2	3.0	2.4	1.9
Acute Monocytic Leukemia	-	-	-	-	-
Chronic Myeloid Leukemia	19	1.6	-	-	2.3
Other Leukemia	28	-	2.4	2.4	2.4
Ill-Defined & Unspecified Sites	362	27.3	28.6	28.3	23.2

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 15. Age-adjusted Mortality Rates, Black Females

Cancer Site	Total Cases	Rates 1999	2000	2001	2002
All Sites	4,128	198.7	195.8	190.7	196.0
Oral Cavity and Pharynx	44	3.3	1.7	1.7	1.7
Lip	-	-	-	-	-
Tongue	11	-	-	-	-
Salivary Gland	-	-	-	-	-
Floor of Mouth	-	-	-	-	-
Gum and Other Mouth	5	-	-	-	-
Nasopharynx	9	-	-	-	-
Tonsil	6	-	-	-	-
Oropharynx	-	-	-	-	-
Hypopharynx	-	-	-	-	-
Digestive System	1,034	52.1	46.9	54.4	49.4
Esophagus	61	3.4	2.5	3.6	2.2
Stomach	127	7.8	4.6	6.1	6.0
Small Intestine	9	-	-	-	-
Colon and Rectum	456	22.1	22.0	22.8	22.9
Colon excluding Rectum	410	19.2	20.5	20.2	20.7
Rectum and Rectosigmoid Junction	46	2.9	1.5	2.6	2.2
Anus	-	-	-	-	-
Liver and Intrahepatic Bile Duct	72	3.5	2.9	4.9	2.3
Liver	52	3.4	1.5	3.7	1.5
Intrahepatic Bile Duct	20	-	1.4	1.2	-
Gallbladder	29	1.7	-	1.3	1.8
Pancreas	257	12.5	12.7	13.5	12.5
Respiratory System	870	42.3	39.8	39.7	42.1
Larynx	15	-	0.9	-	1.1
Lung and Bronchus	852	41.3	38.8	39.6	41.0
Bones and Joints	7	-	-	-	-
Soft Tissue (Including Heart)	42	0.9	1.8	1.6	2.5
Skin (Excluding Basal and Squamous)	14	-	-	-	-
Melanoma of the Skin	9	-	-	-	-
Breast	759	32.2	37.8	31.6	36.0

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 15 (continued). Age-adjusted Mortality Rates, Black Females

Cancer Site	Total Cases	Rates 1999	2000	2001	2002
Female Genital System	480	22.2	23.2	19.5	24.4
Cervix Uteri	127	7.8	5.4	4.3	5.1
Corpus and Uterus, NOS	152	6.3	8.1	6.0	9.1
Corpus Uteri	49	1.4	2.8	1.1	4.0
Uterus, NOS	103	4.9	5.3	4.9	5.0
Ovary	182	7.1	8.8	8.4	9.4
Vagina	-	-	-	-	-
Vulva	10	-	-	-	-
Urinary System	111	4.1	5.8	5.2	6.9
Urinary Bladder	57	1.8	2.5	3.3	3.8
Kidney and Renal Pelvis	51	2.0	3.2	2.0	2.9
Ureter	-	-	-	-	-
Eye	-	-	-	-	-
Brain and Other Nervous System	37	2.2	1.8	1.5	1.2
Endocrine System	14	1.0	0.8	-	-
Thyroid	8	-	-	-	-
Lymphomas	103	5.6	4.9	4.5	3.9
Hodgkin Lymphoma	6	-	-	-	-
Non-Hodgkin Lymphoma	97	5.6	4.3	4.3	3.8
Multiple Myeloma	130	6.2	6.2	7.0	6.0
Leukemias	99	5.1	5.1	4.5	4.0
Lymphocytic Leukemia	23	0.9	1.7	-	1.1
Acute Lymphocytic Leukemia	-	-	-	-	-
Chronic Lymphocytic Leukemia	17	-	1.3	-	-
Myeloid and Monocytic Leukemia	39	2.1	2.1	1.6	1.3
Acute Myeloid Leukemia	25	1.2	1.6	-	1.0
Acute Monocytic Leukemia	-	-	-	-	-
Chronic Myeloid Leukemia	9	-	-	-	-
Other Leukemia	37	2.0	1.3	2.1	1.7
Ill-Defined & Unspecified Sites	383	20.6	19.0	18.0	16.4

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 16. Age-adjusted Mortality Rates, Hispanic Males and Females 1999-2002 Combined

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
All Sites	148.0	1,371	91.7	1,233
Oral Cavity and Pharynx	2.7	28	1.1	14
Lip	-	-	-	-
Tongue	0.7	10	-	-
Salivary Gland	-	-	-	-
Floor of Mouth	-	-	-	-
Gum and Other Mouth	-	-	-	-
Nasopharynx	-	-	-	-
Tonsil	-	-	-	-
Oropharynx	0.6	5	-	-
Hypopharynx	-	-	-	-
Digestive System	46.7	453	28.3	351
Esophagus	4.9	50	1.1	12
Stomach	7.1	77	2.9	40
Small Intestine	-	-	-	-
Colon and Rectum	17.6	155	12.1	151
Colon excluding Rectum	14.6	128	10.4	128
Rectum and Rectosigmoid Junction	3.0	27	1.7	23
Anus	-	-	-	-
Liver and Intrahepatic Bile Duct	7.6	81	3.8	45
Liver	6.4	71	3.1	35
Intrahepatic Bile Duct	1.2	10	0.7	10
Gallbladder	0.8	6	1.8	22
Pancreas	7.2	69	5.8	71
Respiratory System	34.4	332	11.4	146
Larynx	2.1	22	-	-
Lung and Bronchus	32.3	310	11.1	141
Bones and Joints	-	-	-	-
Soft Tissue (Including Heart)	0.6	10	0.5	10
Skin (Excluding Basal and Squamous)	1.1	14	0.5	8
Melanoma of the Skin	0.7	9	0.5	8
Breast	-	-	14.5	223

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 16 (continued). Age-adjusted Mortality Rates, Hispanic Males and Females 1999-2002 Combined

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
Female Genital System	**	**	10.7	152
Cervix Uteri	**	**	2.9	49
Corpus and Uterus, NOS	**	**	3.2	40
Corpus Uteri	**	**	1.5	18
Uterus, NOS	**	**	1.7	22
Ovary	**	**	4.0	57
Vagina	**	**	-	-
Vulva	**	**	-	-
Male Genital System	20.9	135	**	**
Prostate	20.4	130	**	**
Testis	-	-	**	**
Penis	-	-	**	**
Urinary System	8.3	60	2.3	30
Urinary Bladder	4.9	30	1.3	15
Kidney and Renal Pelvis	3.4	30	1.0	15
Ureter	-	-	-	-
Eye	-	-	-	-
Brain and Other Nervous System	2.1	28	1.0	19
Endocrine System	0.5	8	0.7	9
Thyroid	-	-	0.6	6
Lymphomas	7.3	75	4.3	59
Hodgkin Lymphoma	0.2	5	-	-
Non-Hodgkin Lymphoma	7.1	70	4.2	57
Multiple Myeloma	4.1	31	2.7	32
Leukemias	5.2	70	4.1	61
Lymphocytic Leukemia	1.0	18	1.0	15
Acute Lymphocytic Leukemia	0.6	16	0.5	10
Chronic Lymphocytic Leukemia	-	-	-	-
Myeloid and Monocytic Leukemia	3.2	37	1.5	25
Acute Myeloid Leukemia	2.3	28	1.0	16
Acute Monocytic Leukemia	-	-	-	-
Chronic Myeloid Leukemia	0.8	8	0.5	8
Other Leukemia	1.0	15	1.6	21
Ill-Defined & Unspecified Sites	13.6	119	9.4	115

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

** Non-applicable gender

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 17. Comparative Mortality Rates, New Jersey and U.S., 1998-2002
Males

Cancer Site	New Jersey 1998-2002			United States 1998-2002		
Population:	All Races Combined	White	Black	All Races Combined	White	Black
All Sites	249.9	245.9	331.3	247.5	242.5	339.4
Lung	71.0	70.2	93.6	76.3	75.2	101.3
Prostate	29.9	27.3	66.3	30.3	27.7	68.1
Colorectal	27.4	27.3	32.2	24.8	24.3	34.0

Source-NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

Table 18. Comparative Mortality Rates, New Jersey and U.S., 1998-2002
Females

Cancer Site	New Jersey 1998-2002			United States 1998-2002		
Population:	All Races Combined	White	Black	All Races Combined	White	Black
All Sites	176.9	177.8	195.9	165.5	164.5	194.3
Lung	40.8	41.9	40.9	40.9	41.8	39.9
Breast	29.5	29.5	34.3	26.4	25.9	34.7
Colorectal	19.4	19.3	22.8	17.4	16.8	24.1

Source-NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

Table 19. Population Denominators

	1998						1999					
	All Races Male	All Races Female	White Male	White Female	Black Male	Black Female	All Races Male	All Races Female	White Male	White Female	Black Male	Black Female
00-04	288,014	275,502	216,765	207,231	51,523	49,113	287,462	275,114	215,439	205,559	51,197	49,174
05-09	308,255	293,705	232,213	220,859	56,729	54,763	309,684	295,052	232,333	220,962	57,043	54,943
10-14	284,481	270,522	215,139	204,138	51,097	49,257	294,507	280,131	222,127	210,858	53,153	51,437
15-19	267,577	250,965	200,911	186,514	49,344	48,027	269,267	252,487	202,095	187,761	49,142	47,814
20-24	241,812	233,415	182,059	172,121	42,854	44,232	243,493	234,381	182,461	171,854	43,430	44,790
25-29	276,266	277,108	208,919	204,468	45,358	49,078	274,458	274,353	205,803	201,011	44,775	48,643
30-34	335,211	341,302	265,316	258,417	50,212	56,169	325,341	331,258	252,770	249,456	48,809	54,912
35-39	363,391	371,013	289,596	290,215	50,016	56,232	362,946	370,291	287,608	287,859	50,519	56,716
40-44	334,545	347,078	271,216	275,070	41,797	48,936	343,088	354,841	276,591	280,256	43,413	50,334
45-49	285,035	300,883	233,688	240,691	33,632	41,630	291,544	307,297	238,700	245,709	34,346	42,147
50-54	247,349	266,183	206,161	217,355	26,890	34,353	256,150	276,145	212,492	224,316	28,355	35,929
55-59	190,559	207,611	158,367	169,421	22,124	28,177	197,560	215,229	164,332	175,638	22,454	28,751
60-64	152,252	170,210	127,184	140,134	17,742	22,833	154,981	173,309	128,537	141,767	18,376	23,705
65-69	136,296	166,219	117,751	141,495	14,136	19,186	133,493	161,967	114,537	136,884	14,099	19,161
70-74	122,443	163,338	109,418	144,441	10,048	14,715	121,915	161,468	108,283	142,034	10,470	15,057
75-79	92,982	140,874	84,484	126,928	6,663	11,265	94,572	143,041	85,790	128,649	6,799	11,515
80-84	56,042	100,887	51,759	92,337	3,320	7,049	57,365	102,699	52,939	93,898	3,431	7,210
85+	35,740	92,353	33,006	84,954	2,191	6,467	37,495	95,208	34,542	87,341	2,367	6,826
Total	4,018,250	4,269,168	3,203,952	3,376,789	575,676	641,482	4,055,321	4,304,271	3,217,379	3,391,812	582,178	649,064

	2000						2001					
	All Races Male	All Races Female	White Male	White Female	Black Male	Black Female	All Races Male	All Races Female	White Male	White Female	Black Male	Black Female
00-04	287,850	275,421	215,228	205,133	50,835	48,973	287,623	275,663	213,387	203,647	51,804	50,399
05-09	308,995	294,464	230,773	219,527	56,901	54,721	307,040	292,984	228,752	217,960	56,238	53,811
10-14	304,567	289,670	229,491	217,716	55,081	53,422	312,025	297,057	234,624	222,646	56,652	55,058
15-19	273,482	256,395	205,127	190,838	49,719	48,257	282,679	265,899	212,646	198,535	50,727	49,371
20-24	244,954	235,402	182,931	171,618	43,993	45,375	246,542	234,844	183,664	171,516	44,984	45,376
25-29	269,806	268,595	200,873	194,944	43,447	47,690	261,621	258,034	193,941	186,074	42,214	45,900
30-34	318,535	324,547	243,467	242,952	47,986	54,054	315,141	320,293	238,612	237,466	47,931	53,800
35-39	359,558	366,672	282,165	283,072	50,633	56,706	356,802	364,089	278,249	278,672	50,711	57,408
40-44	349,831	360,888	280,655	284,202	44,791	51,529	356,357	366,368	284,874	287,789	46,213	52,568
45-49	300,052	315,790	245,119	252,405	35,314	42,940	310,341	325,193	252,862	259,234	36,630	44,129
50-54	266,017	287,106	219,952	232,047	29,829	37,874	271,936	293,171	224,093	235,813	30,744	39,289
55-59	204,123	222,447	169,465	181,350	23,141	29,457	213,636	233,059	177,651	190,440	23,668	30,080
60-64	156,765	175,336	129,394	142,697	18,696	24,176	159,643	179,144	131,427	145,224	19,035	24,823
65-69	132,169	160,044	112,674	134,403	14,210	19,352	130,829	157,864	110,347	131,001	14,479	20,055
70-74	121,373	159,325	107,307	139,313	10,700	15,392	120,108	156,997	105,818	136,522	10,675	15,505
75-79	95,865	144,777	86,708	129,915	7,009	11,712	95,894	143,876	86,247	128,320	7,274	12,100
80-84	58,897	104,578	54,154	95,385	3,640	7,432	61,627	107,585	56,478	97,910	3,879	7,713
85+	39,464	98,356	36,308	90,061	2,482	7,103	41,397	100,753	38,023	92,185	2,583	7,196
Total	4,092,303	4,339,813	3,231,791	3,407,578	588,407	656,165	4,131,241	4,372,873	3,251,695	3,420,954	596,441	664,581

	2002						2003					
	All Races Male	All Races Female	White Male	White Female	Black Male	Black Female	All Races Male	All Races Female	White Male	White Female	Black Male	Black Female
00-04	287,981	276,552	212,020	202,889	53,186	51,646	287,981	276,552	212,020	202,889	53,186	51,646
05-09	303,447	289,510	225,870	214,836	54,826	52,546	303,447	289,510	225,870	214,836	54,826	52,546
10-14	316,711	301,322	237,205	224,874	57,910	56,198	316,711	301,322	237,205	224,874	57,910	56,198
15-19	288,222	274,041	216,786	204,883	51,725	50,741	288,222	274,041	216,786	204,883	51,725	50,741
20-24	252,550	237,960	188,034	174,407	45,921	45,504	252,550	237,960	188,034	174,407	45,921	45,504
25-29	256,781	251,512	190,100	180,609	41,440	44,775	256,781	251,512	190,100	180,609	41,440	44,775
30-34	311,937	315,253	233,678	230,896	47,848	53,611	311,937	315,253	233,678	230,896	47,848	53,611
35-39	350,810	359,342	271,530	273,012	50,468	57,319	350,810	359,342	271,530	273,012	50,468	57,319
40-44	361,677	370,374	288,154	289,555	47,353	53,924	361,677	370,374	288,154	289,555	47,353	53,924
45-49	320,885	334,816	260,220	266,192	38,380	45,308	320,885	334,816	260,220	266,192	38,380	45,308
50-54	274,420	295,380	225,036	236,447	31,468	40,224	274,420	295,380	225,036	236,447	31,468	40,224
55-59	224,518	244,712	187,235	199,945	24,231	31,108	224,518	244,712	187,235	199,945	24,231	31,108
60-64	167,074	187,656	137,749	152,075	19,515	25,718	167,074	187,656	137,749	152,075	19,515	25,718
65-69	130,417	156,946	109,269	129,351	14,522	20,272	130,417	156,946	109,269	129,351	14,522	20,272
70-74	118,139	154,069	103,178	132,781	10,957	15,912	118,139	154,069	103,178	132,781	10,957	15,912
75-79	96,067	142,981	86,175	126,827	7,370	12,391	96,067	142,981	86,175	126,827	7,370	12,391
80-84	63,797	109,736	58,186	99,531	4,197	8,008	63,797	109,736	58,186	99,531	4,197	8,008
85+	43,737	103,920	40,105	94,949	2,696	7,368	43,737	103,920	40,105	94,949	2,696	7,368
Total	4,169,170	4,406,082	3,270,530	3,434,059	604,013	672,573	4,169,170	4,406,082	3,270,530	3,434,059	604,013	672,573

Source: The National Cancer Institute's SEER Program.

Table 19. Population Denominators
Hispanic Population, 1999-2003

	Male Total	Male 1999	Male 2000	Male 2001	Male 2002	Male 2003	Female Total	Female 1999	Female 2000	Female 2001	Female 2002	Female 2003
00-04	266,596	49,705	50,768	53,361	56,381	56,381	255,102	47,523	48,607	50,972	54,000	54,000
05-09	252,965	48,253	50,020	50,966	51,863	51,863	241,619	46,220	47,641	48,796	49,481	49,481
10-14	239,431	43,686	46,441	48,370	50,467	50,467	230,598	42,036	44,824	46,586	48,576	48,576
15-19	241,293	47,418	48,499	48,614	48,381	48,381	218,999	42,145	43,346	43,900	44,804	44,804
20-24	283,975	54,339	56,459	57,051	58,063	58,063	237,226	46,500	47,449	47,715	47,781	47,781
25-29	288,606	54,762	56,905	58,075	59,432	59,432	250,385	48,513	49,783	50,327	50,881	50,881
30-34	288,617	55,617	55,733	57,635	59,816	59,816	265,031	50,979	51,628	53,150	54,637	54,637
35-39	274,207	51,158	52,786	55,375	57,444	57,444	261,014	48,757	50,521	52,622	54,557	54,557
40-44	222,767	39,458	42,002	44,949	48,179	48,179	221,430	40,182	42,378	44,816	47,027	47,027
45-49	166,852	29,679	31,414	33,749	36,005	36,005	175,070	31,500	33,136	35,176	37,629	37,629
50-54	128,553	23,548	24,848	25,901	27,128	27,128	140,064	25,761	27,208	28,291	29,402	29,402
55-59	94,431	17,164	17,926	19,007	20,167	20,167	106,628	19,369	20,174	21,621	22,732	22,732
60-64	71,723	13,318	13,871	14,438	15,048	15,048	82,484	15,099	15,820	16,597	17,484	17,484
65-69	49,970	9,186	9,569	10,043	10,586	10,586	63,393	11,693	12,086	12,682	13,466	13,466
70-74	35,172	6,365	6,625	7,164	7,509	7,509	47,286	8,606	8,954	9,548	10,089	10,089
75-79	21,150	3,531	3,840	4,279	4,750	4,750	32,476	5,710	6,061	6,547	7,079	7,079
80-84	11,097	1,886	1,982	2,203	2,513	2,513	20,081	3,545	3,704	4,048	4,392	4,392
85+	7,883	1,242	1,392	1,619	1,815	1,815	17,566	2,993	3,201	3,544	3,914	3,914
Total	2,945,288	550,315	571,080	592,799	615,547	615,547	2,866,452	537,131	556,521	576,938	597,931	597,931

Source: The National Cancer Institute's SEER Program.

Table 20. Age Distribution (%) of Incidence Cases in New Jersey, 1999-2003
All Races, Both Sexes

Site	0-19	20-34	35-44	45-54	55-64	65-74	75-84	85+	All Ages	Cases
All Sites	0.9%	2.3%	5.6%	12.5%	20.2%	26.8%	24.1%	7.6%	100%	231,361
Oral Cavity and Pharynx	0.4%	2.2%	7.9%	20.0%	23.5%	22.6%	17.4%	6.0%	100%	4,421
Esophagus	0.0%	0.3%	2.7%	12.0%	22.9%	29.8%	23.5%	8.7%	100%	2,266
Stomach	0.0%	1.4%	4.5%	8.8%	16.7%	26.5%	29.6%	12.3%	100%	4,144
Colon and Rectum	0.0%	0.8%	3.2%	8.9%	16.4%	26.2%	31.7%	12.8%	100%	27,277
Male	0.0%	0.8%	3.4%	9.7%	18.9%	28.7%	29.4%	9.0%	100%	13,557
Female	0.0%	0.8%	2.9%	8.1%	14.0%	23.8%	34.0%	16.5%	100%	13,720
Colon	0.0%	0.8%	2.7%	7.9%	15.0%	26.0%	33.5%	14.1%	100%	19,772
Rectum	0.0%	0.8%	4.4%	11.6%	20.1%	26.8%	27.0%	9.3%	100%	7,505
Liver &.Intrahepatic bile duct	1.0%	1.1%	3.8%	16.0%	19.0%	25.4%	24.7%	9.0%	100%	2,468
Pancreas	0.0%	0.3%	2.5%	7.8%	16.9%	27.5%	32.1%	12.7%	100%	5,436
Lung and Bronchus	0.0%	0.2%	2.3%	8.7%	20.8%	32.1%	28.9%	7.0%	100%	30,064
Male	0.0%	0.2%	2.0%	8.5%	21.5%	33.4%	28.5%	6.0%	100%	15,963
Female	0.0%	0.2%	2.6%	8.9%	20.1%	30.7%	29.3%	8.1%	100%	14,101
Melanoma of the Skin	0.9%	6.3%	12.2%	16.8%	18.3%	21.5%	18.0%	6.1%	100%	7,823
Breast (Female)	0.0%	1.9%	11.1%	21.6%	21.5%	20.5%	17.5%	6.0%	100%	32,627
Cervix Uteri	0.2%	13.3%	23.7%	24.2%	15.7%	11.5%	8.6%	2.8%	100%	2,289
Corpus and Uterus, NOS	0.0%	0.8%	5.1%	16.8%	28.4%	25.5%	18.5%	4.8%	100%	7,014
Ovary	0.9%	2.7%	8.5%	18.8%	21.4%	20.3%	20.0%	7.5%	100%	3,849
Prostate	0.0%	0.0%	0.5%	7.8%	26.3%	37.9%	23.4%	4.1%	100%	38,049
Testis	5.2%	43.9%	32.8%	12.8%	3.0%	1.1%	1.1%	0.2%	100%	1,220
Urinary Bladder	0.1%	0.5%	2.2%	7.6%	17.2%	29.6%	31.9%	11.0%	100%	11,463
Kidney and Renal Pelvis	1.5%	1.3%	5.6%	14.7%	21.7%	27.3%	22.5%	5.3%	100%	6,119
Brain & Nervous System	11.7%	8.0%	9.1%	15.4%	16.6%	19.2%	16.0%	3.9%	100%	3,022
Thyroid	1.7%	16.6%	23.5%	22.6%	16.3%	11.3%	6.8%	1.2%	100%	4,429
Hodgkin Lymphoma	11.2%	31.9%	18.2%	12.4%	9.9%	8.1%	6.6%	1.7%	100%	1,440
Non-Hodgkin Lymphoma	1.6%	4.0%	7.8%	13.7%	17.4%	22.6%	24.6%	8.4%	100%	9,443
Myelomas	0.0%	0.6%	2.9%	11.1%	18.4%	27.5%	28.9%	10.5%	100%	2,654
Leukemia	8.9%	4.1%	5.2%	9.9%	14.6%	21.4%	26.2%	9.6%	100%	5,544
Acute Lymphocytic	58.3%	8.9%	4.6%	5.5%	6.3%	7.9%	6.1%	2.3%	100%	605
Chronic Lymphocytic	0.2%	0.4%	2.2%	9.3%	18.7%	26.4%	31.5%	11.4%	100%	1,828
Acute Myeloid	5.5%	6.1%	6.3%	10.4%	14.6%	22.3%	26.3%	8.6%	100%	1,701
Chronic Myeloid	1.5%	5.7%	10.2%	13.2%	14.4%	20.8%	26.3%	7.8%	100%	665
Other Leukemia	4.9%	3.9%	3.4%	6.2%	8.1%	19.2%	32.7%	21.6%	100%	385

Table 21. Median Age of Cancer Patients at Diagnosis, New Jersey 1999-2003
By Primary Cancer Site, Race and Sex

	All Races			Whites			Blacks		
Site	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Sites	68	69	67	69	69	68	64	65	63
Oral Cavity and Pharynx	63	61	67	64	62	69	57	57	57
Esophagus	69	67	72	70	68	73	64	64	64
Stomach	72	70	75	73	71	76	69	67	71
Colon and Rectum	73	71	75	74	72	75	67	66	68
Colon	74	72	75	75	73	76	68	67	69
Rectum	70	68	72	71	69	73	65	63	66
Liver & Intrahepatic bile duct	69	66	74	71	68	75	60	57	67
Pancreas	73	71	75	73	71	76	70	68	72
Lung and Bronchus	71	70	71	71	71	71	66	66	66
Melanoma of the Skin	62	64	59	62	64	59	65	59	70
Breast	61	67	61	62	69	62	58	62	58
Cervix Uteri	*	*	49	*	*	49	*	*	51
Corpus and Uterus, NOS	*	*	64	*	*	64	*	*	65
Ovary	*	*	63	*	*	64	*	*	60
Prostate	*	69	*	*	69	*	*	66	*
Testis	*	35	*	*	35	*	*	34	*
Urinary Bladder	73	72	74	73	72	74	70	68	72
Kidney and Renal Pelvis	66	65	69	67	66	70	62	62	63
Brain & Nervous System	58	57	60	59	58	61	51	48	54
Thyroid	48	53	47	48	53	47	51	53	50
Lymphoma	65	62	68	67	64	69	50	49	52
Hodgkin Lymphoma	38	39	37	39	40	38	38	38	36
Non-Hodgkin Lymphoma	68	65	70	69	67	71	53	50	56
Myeloma	71	70	73	72	70	74	67	67	68
Leukemia	68	68	69	70	69	71	59	59	59
Acute Lymphocytic	14	16	12	15	16	12	13	13	13
Chronic Lymphocytic	72	71	74	73	72	75	66	66	67
Acute Myeloid	68	68	69	70	70	70	59	60	56
Chronic Myeloid	68	68	67	70	70	70	57	59	54
Other Leukemia	76	75	77	77	76	79	54	46	72

* Non-applicable gender.